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1 
N-ALKYL AND N-ACYL DERIVATIVES OF 
3,7-DIAZABICYCLO-[3.3.l]NONANES AND 
SELECTED SALTS THEREOF AS 
MULTI-CLASS ANTIARRHYTHMIC AGENTS 
BACKGROUND OF THE INVENTION 
1. Field of The Invention 
This invention relates to antiarrhythmic compositions. 
Specifically, this invention relates to certain members of the 
family of 3,7-diazabicyclo[3.3.l]nonanes and highly 
selected derivatives thereof. 2. Description of the Prior Art 
3-Azabicyclo[3.3.l]nonanes (3-ABN), 3,7-diazabicyclo 
[3.3.l]nonanes (3,7-DBCN), and certain derivatives thereof 
are known and have been documented in the literature in two 
reviews. These reviews are: (a) Chemical Reviews, Volume 
81, No. 2, pages 149-174 (1981), entitled "Chemistry of 
3-Azabicyclo[ 3.3.l]nonanes" by R. Jeyaraman and S. Avila 
and (b) Topics in Stereochemistry, Volume 20, E. L. Elie! 
and S. H. Wilen, Eds., Interscience-Wiley, Publishers, New 
York, Chapter entitled "Conformational Analysis of Bicyclo 
[3.3.l]nonanes and Their Hetero Analogs" by N. S. Zefirov 
and V. A. Palyulin, 1990. These reviews cover synthesis, 
reactions and certain aspects of the stereochemistry of such 
systems. These reviews also acknowledge that there is 
resemblance of the title compounds to aza- and diazaada-
mantanes in conformation and stereochemistry and that such 
systems have been obtained by Mannich reactions involving 
the condensations of certain ketones with a primary amine. 
According to the chemical literature, some derivatives of 
3-ABN and 3,7-DBCN have exhibited useful biological 
properties including analgesic, antiangina, antitussive, anti-
pyretic, and antiarrhythmic agent (AAA) activity. In U.S. 
Pat. Nos. 4,581,361; 4,778,892; 4,910,311; 4,980,468; 
5,043,445; 5,084,572; and 5, 110,933, for example, such 
Q 
(H3C)2CHN 
(H3C),CHN 
(H3C)2CHN 
(H3C)2CHN 
(H3C),CHN 
2 
materials are disclosed and claimed as antiarrhythmic 
agents. 
The potential use of multi-class action antiarrhythmic 
agents [classification of action of antiarrhythmic agents has 
5 been made; see E. M. Vaughn Williams, "A Classification of 
Antiarrhythmic Drugs Reassessed After a Decade of New 
Drugs", Journal of Clinical Pharmacology, Volume 24, 
pages 129-147 (1984)] is now recognized. The few agents 
with some multi-class action have also been reviewed in 
IO "Cardiovascular Drugs", James A. Bristol, Ed., Wiley-Inter-
science Publishers, New York, 1986; chapter 2 entitled 
"Screening Methods and Test Models for Evaluation of 
Cardioactive Drugs", by Robert J. Lee, Richard J. Gorczyn-
ski, and Robert D. E. Reynolds. See also chapter 7 in this 
15 reference entitled "Antiarrhythmic Agents" which is 
authored by Johannes Hartenstein and Bernd Wagner. 
Specifically, this invention is related to the above deriva-
tives of 3,7-DBCN [1-46] and precursors [47- 100, 
108-112) thereof for controlling life-threatening arrhyth-
20 mias associated with the "sudden death syndrome" with 
individuals who experience heart attacks caused by coronary 
heart disease. The objective of the present invention is to 
provide useful compositions that display multi-class antiar-
rhythmic agent (AAA) activity. Fulfillment of this object and 
25 the presence and fulfillment of other objects will be apparent 
upon complete reading of the specifications and claims 
herein. The novelty of the invention lies in the the non-
predictable, multi-class AAA activity induced by very spe-
cial substituents in the compositions. 
30 
SUMMARY OF INVENTION 
The present invention involves novel derivatives (salts) of 
3,7-diazabicyclo[3.3.l]nonanes having the basic formula: 
;\'\ 
Q ZY HX[or2HX] 
z 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
\_j_J 
y 
X = 004, Br, Cl, HS04 
citrate, fumarate, rnaleate 
4-NC(O)C6H4N02 
4-NC(O)C6H4NH2 
4-NC(O)C6H4NHS02CH3 
4-NC(O)C6H4 - F 
f":::-N 
4-NC(O)C6H.-N ~ 
NUMBER 
1 
2 
3 
4 
5 
6 
7 
8 
Q 
(::>-CH2N 
(::>-cH2N 
(::>-rn2N 
(::>-rn2N 
(::>-cH2N 
(::>-rn2N 
(::>-cH2N 
(::>-cH2N 
(::>-cH2N 
(::>-cH2N 
n-C3H7N 
n-C,H7N 
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-continued 
r\\ 
Q ZY HX [or2HX] 
\_L/ X = Cl04, Br, Cl, HS04 
citrate, fumarate, maleate 
z 
CH 
s 
< ) 
s 
CH2 
s 
< ) 
s 
CH2 
CH2 
CH2 
CH2 
CH2 
y 
~N 
4-NCH2CH(OAc)C6"4-N V 
NCH(CH3h 
NCH(CH,h 
SUMMARY OF INVENTION 
4-NC(O)C6H4 - Cl 
4-NC(O)C6"4 - F 
~N 
4-NC(O)C6"4-N V 
~N 
4-NCH2C(O)C6"4-N V 
~N 
4-NCH2CH(OH)C6"4-N V 
4-NC(O)C6H4 - N02 
4-NC(O)C6H4 - NH2 
4-NC(O)C6H4 - NHS02CH3 
Additional 3,7-DHBCNS-3 
4-NC(O)C6H4 - F 
NUMBER 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
4 
5,468,858 
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-continued 
/\\ 
Q ZY HX[or2HX] 
\_j_/ X = CIO4, Br, Cl, HSO4 
citrate, fumarate, maleate 
Q z y NUMBER 
n-CsH1N CH2 f'::-N 25 
4-NCH(OH)C5R4-N v1 
n-CsH7N CH2 ('::- N 26 
4-NCH(OAc)C5R4-N V 
n-CsH7N CH2 4-NC(O)C6H4 -NO2 27 
n-CsH7N CH2 4-NC(O)C6H4 - NH2 28 
n-C3H7N CH2 4-NC(O)C6H4 -NHSO2CH3 29 
n-CsH7N CH2 4-NCH2C(O)C6H4 - F 30 
n-C3H7N CH2 ('::- N 31 
4-NCH2C(O)C5R4-N v1 
n-CsH1N CH2 4-NCH2C(O)C6H4 -NO2 32 
n-CsH7N CH2 4-NCH2C(O)C6H4 - NH2 33 
n-CsH7N CH2 4-NCH2C(O)C6H4 - NHSO2CH3 34 
SUMMARY OF INVENTION 
s CH2 4-NC(O)C6H4 -F 35 
s CH2 ['::- 36 N 
4-NC(O)C5R4-N v1 
s CH2 ['::- 37 N 
4-NCH(OH)C5R4-N v1 
s CH2 ('::- N 38 
4-NCH(OAc)C5R4-N v1 
s CH2 4-NC(O)C6H4 - NO2 39 
s CH2 4-NC(O)C6 H4 - NH2 40 
s CH2 4-NC(O)C6H4 - NHSO2CH3 41 
s CH2 4-NCH2 C(O)C6 H4 - F 42 
s CH2 ('::- N 43 
4-NCH2C(O)C5R4-N v1 
s CH2 4-NCH2C(O)C6H4 - NO2 44 
s CH2 4-NCH2C(O)C6 H4 - NH2 45 
s CH2 4-NCH2 C(O)C6 H4 - NHSO2CH3 46 
5,468,858 
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The present invention also provides for novel intermedi-
ates of the class of 3,7-diazabicyclo[ 3.3.1]-nonan-9-ones 
having the formula: 
R-/:i}) 
R y NUMBER 
(H3C)2CHN NCH(CH3)z 47 
[>-rn2 
NCH2C•Hs 48 
I\\ 
Q ZY 
\_LJ 
Q z y 
(H3C)zCHN CH2 4-NC(O)C6H4NO2 
(H3C)2CHN CH2 4-NC(O)C6H4NH2 
(H3C)2CHN CH2 4-NC(O)C.H4NHSO2CH3 
(H3C)zCHN CH2 4-NC(O)C6H4 - F 
(H3C}2CHN CH2 f"'::-N 
4-NC(O)C6H,-N V 
(H3C)2CHN CH2 4-NCH2C(O)C6H, -F 
(H3C)2CHN CH2 f"'::- N 
4-NCH2C(O)C6H,-N V 
(H3C}2CHN CH2 f"'::- N 
4-NCH2CH(OH)C6H,-N V 
(H3C)2CHN CH2 f"'::- N 
4-NCH2CH(OAc)C6H,-N V 
(H3C)2CHN CH2 NCH(CH3)z 
Additional 3,7-DHBCNS-2 
[>-cH2N CH2 
NC(O)C6H5 
[>-cHiN 
CH2 NCH2C6H5 
[>-cH2N CH2 
4-NC(O)C6H4 - Cl 
[>-cH2N CH2 
4-NC(O)C6H4 - F 
[>-CH2N 
CH2 f"'::- N 
4-NC(O)C6H,-N V 
5 
10 
-continued 
•-(]:!) 
R y NUMBER 
n-C3H7 NCH2C.H5 49 
The invention further provides additional 3,7-diazabi-
cyclo[3.3.l]nonanes of the formula: 
NUMBER 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
9 
Q 
n-C3H7N 
n-CsH7N 
n-C3H7N 
n-C3H7N 
n-C3H7N 
n-C3H7N 
n-C3H 7N 
n-C3H7N 
n-C3H 7N 
n-C3H7N 
n-C3H7N 
s 
s 
s 
s 
5,468,858 
z 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
CH2 
10 
-continued 
/\\ 
Q zy 
\_j_/ 
y 
~N 
4-NCH2C(O)C614-N v1 
~N 
4-NCH2CH(OH)C614-N v1 
4-NC(O)C6H4 -NO2 
4-NC(O)C6H4 - NH2 
4-NC(O)C6H4 - NHSO2CH3 
Additional 3,7-DHBCNS-3 
4-NC(O)C6H4 -F 
~N 
4-NC(O)C614-N v1 
~N 
4-NCH(OH)C614-N v1 
~N 
4-NCH(OAc)C614-N v1 
4-NC(O)C6H4 - NO2 
4-NC(O)C6H4 - NH2 
4-NC(O)C6H4 - NHSO2CH3 
4-NCH2C(O)C6H4 - F 
4-NCH2C(O)C6H4 - NO2 
4-NCH2C(O)C6H4 - NH2 
4-NCH2C(O)C6 H4 -NHSO2CH3 
Additional 3,7-DHBCNS-4 
~N 
4-NC(O)C614-N v1 
~N 
4-NCH(OH)C614-N v1 
~N 
4-NCH(OAc)C614-N v1 
NUMBER 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
5,468,858 
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-continued 
I\\ 
Q ZY 
\_LJ 
Q z y NUMBER 
s CH2 4-NC(O)C6H4 - NO2 86 
s CH2 4-NC(O)C6H4 - NH2 87 
s CH2 4-NC(O)C6H4 -NHSO2CH3 88 
s CH2 4-NCH2C(O)C6H4 - F 89 
s CH2 f':::-N 90 
4-NCH2C(O)C6tt.-N v1 
s CH2 4-NCH2C(O)C6H4 - NO2 91 
s CH2 4-NCH2C(O)C6H4 - NH2 92 
s CH2_ 4-NCH2C(O)C6H4 - NHSO2CH3 93 
Additional 3,7-DHBCNS-5 
(H3C)2CHN CH2 4-NC(O)CH2C6tt_NO2 94 
(H3C)2CHN CH2 4-NC(O)CH2C6H4NO2.H0O4 95 
(H3C)2CHN CH2 4-NC(O)CH2C6H4NH2 96 
{H3C)2CHN CH2 4-NC(O)CH2C6H4 - NHSO2CH3 97 
(H3C)2CHN CH2 4-NC(O)CH2C6H4 - NHSO2CH3.HC1O4 98 
(H,C)2CHN CH2 4-NC(O)CH2C6H4 - NHAc 
(H3C)2CHN CH2 4-NC(O)CH2C6H4NHAc.H0O4 
(H,Cl2CHN CH2 4-NCH(O)C6H4 - NHAc 
(H,Cl2CHN CH2 4-NCH(O)C6H4 - NHAc.H0O4 
(H3C),CHN CH2 4-NCH2CH(OHJC6H4 - F 
(H,C)2CHN s NCH(CH3)z 
C ) 
s 
[:>---cH2N s 
NCH(CH3 )2 
C ) 
s 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The chemical compositions according to the preferred 
embodiments of this invention are heteroimclear ring 
organic compounds based on 3,7-diheterabicyclo[3.3.1] 
nonanes with the general structures as follows: 
654 65 4 
(2>-c>< 2 °> 
"" '" 'j ' 
I\\ 
Q 9Z Y 
\_LJ 
8 I 2 
Most structures contain nitrogen at the 3,7-positions 
(1-34 and 47-81), but structures 35-46 and 82- 93 contain 
sulfur (S) at the 7-position. Substituents at the 3-position (Y) 
vary with N-acyl groups [1-5, 12, 14, 16, 17, 20-24, 27-29, 
35,36,39-41,50-54,60,62-64,67-71, 74-76,82,83,86-
99 
100 
108 
109 
110 
111 
112 
88, 94-100,108,109] and N-alkyl groups [6-11, 13, 15, 18, 
19,25,26,30-34,37,38,42-49,55-59,61,65,66, 72, 73, 
77-81, 84, 85, 89-93, 110-112]. Substituents (Q) at the 
45 7-position are either N-isopropyl, N-cyclopropylmethyl, 
N-benzyl or S. Salts [HX=hydroperchlorate, HCl, HBr, 
H2SO4 , citrate, fumarate and maleate] are included. It is not 
intuitively obvious that the substituents described would 
elicit such remarkable multi-class AAA, and thus the agents 
50 described are novel. The bridging group (Z) is CH2 group 
except for 11 and 15 in which a 9,9-(1,3-dithian-2-yl) group 
is present at the 9-position or in intermediates 47-49 where 
a carbonyl [C=O] group is present. 
These compounds are the active ingredients for potential 
55 agents and/or intermediates for the active components of 
potential agents for the treatment of life-threatening rhythm 
disorders of the heart. They exhibit antiarrhythmic activity 
in animal models and are therefore viable candidates for the 
treatment of such disorders in humans who experience 
60 sudden heart attach or major infarctions of the heart. 
In the Cardiac Arrhythmia Suppression Trial (CAST) 
["The Cardiac Arrhythmia Suppression Trial Investigators, 
Preliminary Report: Effect of Encainide and Flecainide on 
Mortality in Randomized Trial of Arrhythmia Suppression 
65 After Myocardial Infarction" in the New England Journal Of 
Medicine, Volume 321, pages 406-412 (1989). See also 
"Mortality and Morbidity in Patients. Receiving Encainide, 
5,468,858 
13 
Flecainide, or Placebo-The Cardiac Arrhythmia Suppression 
Trials" in the New England Journal of Medicine, Volume 
324, pages 781-788 (1991), by D.S. Echt, MD. Liebson, L. 
B. Mitchell, el. al. See also "CAST: Implications for Drug 
Development" in Clinical Pharmacology Therapy", Volume 5 
47, pages 553-556 (1990) by R. L. Woosley], it was reported 
that the proarrhythmic effects of antiarrhythmie agents were 
responsible for inducing a statistically significant higher 
incidence of sudden cardiac death than the mortality rate of 
those patients taking a placebo agent [see also E. M. 10 Vaughn-Williams "Significance of Classifying Antiarrhyth-
mic Actions Since the Cardiac Arrhythmia Suppression Trial 
(CAST)" Journal of Clinical Pharmacology, Volume 31, 
pages 123-1356 (1991); P. J. Podrid and R.-I. Fogel, 
"Aggravation of Arrhythmia by Antiarrhythmic Drugs, and 
the Important Role Underlying Ischemia", American Journal 15 
of Cardiology, Volume 70, pages 100-102 (1992); H. L. 
Greene, D. M. Roden, R. J. Katz, R. L. Woosley, D. M. 
Salemo, R. W. Henthorn, and the CAST Investigators, "The 
Cardiac Arrhythmia Suppression Trial: First CAST ... Then 
CAST-II" in the Journal of American College of Cardiology, 20 
Volume 19, pages 894-898 (1992)]. Members of the DBCN 
family members described herein this document do not 
commonly show significant proarrhythmic effects but do 
reduce rates of or abolish induced arrhythmias in animal 
models. Moreover, the commonly used agents in the CAST 
14 
reagents as for the required key precursors of systems 47 and 
48 have been expressed in U.S. Pat. No. 5,084,572. How-
ever, modifications have been necessary and these are delin-
eated in this document. For example, and as outlined in 
Reaction Scheme A, the synthesis of the bicyclic ketones 47 
and 48 originate from a Mannich or Mannich-type conden-
sation starting from l-isopropyl-4-piperidinone (101) or 
l-benzyl-4-piperidinone (102). Ketones 101 and 102reacted 
with isopropylarnine or cyclopropylmethylarnine and 
paraformaldehyde in the presence of acetic acid/hydrochlo-
ric acid/methanol to yield 47 and 48, respectively. The 
conditions are critical for good results. In addition, ketone 
101 was allowed to react with benzylarnine under similar 
conditions to give bicyclic system 103 {3-isopropyl- 7-ben-
zyl-3,7-diazabicyclo[3.3.l]nonan- 9-one}. Reduction of 
bicyclic ketone 47 was effected with hydrazine in triethylene 
glycol/KOH media to generate 59 which was converted to 
its hydroperchlorate 10. In similar fashion, removal of the 
carbonyl oxygen atom in 103 was accomplished to give 104 
{ 3-isopropyl-7-benzyl-3,7-diazabicyclo-[ 3.3.l]nonane} as 
illustrated. Generation of an intermediate thioketal from 47 
followed standard 
REACTION SCHEME A 
>-(J-o 
101 
ll(H004) 
t. HS(CH2)zSH 2.H004 (H2CO)n/i-PrNH2 '> H2NNH2rrEG 
/~~H=o~A~C/H~c=1--7~ 47 KOH 
HCJ04 > 59 > lO(HCJ04) 
""' (H2CO)n/PhCH2NH2 
HOAc/HCl >>-< ) O >]_H_2NNH~K=~~~G->->-N ~ N_/Ph 
103 \...h 104 
102 
(H2CO)n/c-PrCH2NH2 
HOAc/HCl 
study depressed myocardial contractile function whereas the 
members of DBCN described in this document have been 55 
shown to increase mean blood pressure. Cardiac mechanical 
depression may excaberate the risk of sudden death, par-
ticular} y in patients with preexisting coronary heart disease. 
Representative reaction schemes are provided to illustrate 
the general methodology utilized in preparing the com-
pounds to be claimed. Typical procedures using common 
procedures, but only salt 11 was isolated. The same proce-
dure used to obtain 47, 48 and 103 can be used to obtain 49. 
Diarnine 104 is a key intermediate for the preparation of 
1-9 and intermediates 50-58. Debenzylation of 104 is 
initiated as shown in Reaction Scheme B utilizing ammo-
nium formate in the presence of palladium-on-carbon to 
yield 105. Aroylation of 105 with 4-O2NC6 H4C(O)Cl or 
4-F-C6 H4C(O)Cl as 
5,468,858 
15 16 
REACTION SCHEME B 
y 
N 
IO< 10"'"" > [ ( NH 
HCO2Nl4 ~
105 
. TiCl3/AcOH '> 
51 
CISO2CH3 H0O4 
50 HzO 7 > 52 > 3(H0O4) 
53 Imidazole ~ HCl04 ~ 
'-=K-2C~0~3-/cr_o_w_n-eth-er--7- 54 ?' 5<2H0O4) 
shown led to amides 50 and 53, respectively. Conversion of 
the nitro group in 50 to an amino group was done with 
TiCl3'AcOH to yield 51 which, in turn, was N-sulfonated 
with mesyl chloride to give 52. Addition of perchloric acid 
usual manner or with imidazole/K2CO3 to 56 as shown in 
20 Reaction Scheme D. Treatment of 56 with HCIO4 led to salt 
to this amide gave salt 3. Treatment of 53 with imidazole in 
the presence of K2CO3'l8-crown-6 ether proceeded 
smoothly, and the intermediate 54 was converted directly to 25 
salt 5. 
In Reaction Scheme C, bicyclic ketone 48 was reduced 
under the same conditions as described above to yield 
diamine 61. Formation of the salt 13 followed easily from 
61. Conversion of ketone 48 to the intermediate thioketal 30 
was facile, and the latter was then converted to salt 15. 
Debenzylation of 61 was achieved as shown to yield key 
intermediate 106 which was used at once. Aroylation of 106 
with benzoyl chloride or 4-ClC6H4C(O)Cl led to 60 and 62, 
respectively. Conversion of 60 and 62 to salts 12 and 14, 
respectively, followed in standard fashion. 
REACTION SCHEME C 
15 
13 
7. Reduction of 56 with sodium borohydride gave diamine 
57 which was converted to salt 8. 
t. HS(CH2)2SH 
l2.H004 jmo, ~C~6H=s=C~(O=)=Cl~- 60H004 > 12 NaOH/H2CC12 
48 
H2NNH2/KOH > 61 10%Pd/C HCO2Nl4 4-0C6li4C(O)Cl NaOH/H2CC12 
Alkylation of intermediate 105 with 4-fluorophenacyl 
chloride (107) gave 55 which was converted to salt 6 in the 
5,468,858 
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REACTION SCHEJ\,ffi D 
98 
ClCH2C(O)C6I¼-4-F (107) 
NaOH/H2CC12 
The following are representative examples of the com-
pounds cited previosuly in this invention. 
EXAMPLE I 
3-Isopropyl-7-benzyl-3,7-diazabicyclo[3.3.1 ]nonan-9-one 
(103) 
56 
lbs, 1 H, H(l)], 2.04-2.32 [m, 3 H, ring protons], 2.67 (dd, 
2 H, ring protons), 2.94 (dd, 1 H, ring proton), 3.20 (d, 1 H, 
20 ring proton), 3.39 (d, 1 H, ring proton), 7.13 (d, 2 H, Ar-H), 
7.85 (d, 2 H, Ar-H); 13C NMR (DCC13 ) ppm 15.89, 19.46 
(CH3 isopropyl), 28.81 29.57 C(l,5), 32.04 C(9), 46.55 
(C-H isopropyl), 51.79, 52.31, 54.26, 54.85 C(2,4,6,8), 
25 Ketone (103) was prepared by the method in U.S. Pat. No. 
123.52, 127.60, 143.91, 147.62 (Ar-C), 167.58 (NC=O). 
Mass spectral (EI) data calcd for C17H23N3O3 rn/e (M+): 
317.1739. Found: 317.1750. Anal. Calcd for C17H23N3O3 : 5,084,572 C, 64.33; H, 7.30; N, 13.24. Found: C, 64.06; H, 7.36; N, 
12.97. 
Gaseous HCl was generated in a flask containing solid 
EXAMPLE II 
3-Isopropyl-7-benzyl- 3,7-diazabicyclo[ 
3.3.l]nonane (104) 
Diamine (104) was prepared by the method in U.S. Pat. 
No. 5,084;572 
30 NaCl which was treated with H2 SO4 (15 ml) in a dropwise 
manner, and the gas generated was passed through a CaC12 
drying tube. To a flask equipped with a magnetic stirrer and 
an ice bath was added HClcg) to a chilled (5° C.) solution of 
amide 50 (2.5 g, 7.88 mmol) in ether (150 ml) over a 15 min 
EXAMPLE III 
3-Isopropyl-3,7-diazabicyclo[3.3.l]nonane (105) 
35 period. The mixture was allowed to stir an additional 15 min 
at 0°-5° C. A white precipitate was filtered and washed with 
cold ether. The solid was recrystallized (methanol:ether, 
1:1), and the white needles collected were washed (cold 
This diamine (105) was prepared by the method in U.S. 
Pat. No. 5,084,572 40 
ether) and dried to give 2.09 g (74.9%) of salt 1; mp 
258°-259° C. IR (KBr) 3410 (N-H), 3100, 3040 (Ar-H), 
2950, 2860 (C-H), 1655 (NC=O) cm-1; 1H NMR (D2O) 
151.43 [d, 6 H, CH3 isopropyl], 2.01 lbs, 2 H, H(9)], 2 H, 
H(l,5)], 3.39-3.67 [m, 9 H, H(2,4,6,8)] and C-H isopropyl], 
7.71 [d, 2 H, Ar-H], 8.33 [d, 2 H, Ar-H], 13C NMR (D2O) 
EXAMPLE IV 
3-(4-Nitrobenzoyl)-7-isopropyl-3,7-diazabicyclo-
[3.3.l]nonane Hydrochloride (1) and 
3-(4-Nitrobenzoyl)-7-isopropyl-3,7-diazabicyclo-
[3.3.l]nonane (50) 
A flask was equipped with a magnetic stirrer, a condensor 
with N2 inlet, an addition funnel and two glass stoppers. To 
45 ppm 19.43 [CH3 isopropyl], 29.56 [C(l,5,9)], 49.11, 53.32 
[s, ring carbons],63.67 [C-H isopropyl], 126.89, 130.73, 
143.84, 151.10 [Ar-C], 175.77 [NC=O]. Mass spectral (EI) 
data calcd for C17H24N3O3Cl rn/z (M+): 317.1739 (-HCl). 
Found: 317.1761. Anal. Calcd for C17H24N3O3Cl: C, 57.70; 
50 H, 6.84; N, 11.58. Found: C, 57.86; H, 6.72; N, 11.65. 
a mixture of amine 105 (3.82 g, 22. 70 mmol) in H2CC12 (25 
ml) and 10% NaOH (22.76 g, 56.80 mmol) was added 
dropwise a solution of 4-nitrobenzoyl chloride (4.63 g, 
24.90 mmol) in H2CC12 (15 ml) over a period of 15 min. 
Stirring of the mixture was continued for an additional 3 h 55 
under N2 . To the heterogenous mixture was added H2O (100 
ml), and two layers were separated. Further extracts 
(H2CC12 , 3x50 ml) of the aqueous layer were combined, and 
the solution was dried (Na2 SO4), filtered and concentrated to 
give a viscous yellow oil which solidified upon standing. 60 
This yellow solid was dissolved in ether, and the solution 
was filtered. The filtrate was concentrated and then dried by 
vacuum to give 6.79 g (94.3 %) of a light yellow solid 50; 
mp 119°-120° C. IR (KBr) 3090, 3005 (Ar-H), 2920, 2880, 
2770 (C-H), 1635 (NC=O), 760 (C-H out of plane, para) 65 
cm-1; 1H NMR (DCC13) 00.56 (d, 3 H, CH3 isopropyl), 0.69 
(d, 3 H, CH3 isopropyl), 1.34 [m, 2 H, H(9)ax, H(5)], 1.61 
EXAMPLEV 
3-(4-Aminobenzoyl)-7-isopropyl-3,7-diazabicyclo-
[3.3.l]nonane Hydrochloride (2) and 
3-( 4-Aminobenzoyl)-7-isopropyl-3, 7-diazabicyclo-
[3.3. l ]nonane (51) 
To a flask equipped with a magnetic stirrer was added 
amide 50 (9.17 g, 28.90 mmol) in AcOH:H2O(1:1,100 ml). 
To this solution was added TiC13 (16%, 195.0 g, 202.3 
mmol) in one portion, and the mixture was stirred at RT for 
7 min. The deep purple solution was made basic (pH-12) 
with 20% NaOH until a blue color persisted. Extraction 
(H2CC12 , 4x90 ml) was followed by washing with H2O (2x 
100 ml) and brine (100 ml). After drying (Na2SO4 ), the 
solution was filtered and concentrated to give 7.34 g (86.2%) 
5,468,858 
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of an off-white solid 51; mp 149°-150° C. IR (KBr) 3340, 
3220 (N-H), 3060, 3020 (Ar-H), 2980, 2800 (C-H), 1640 
(NC=O) cm-1. 1H NMR (DCC13) o0.98 (bs, 6 H, CH3 
isopropyl), 1.67 [m, 3 H, H(5), H(9)], 1.91 [s, 1 H, H(l)], 
2.41 (bs, 2 H, ring proton), 2.72 (s, lH, ring proton), 3.02 5 
(bs, 2 H, ring protons), 3.31 (d, 1 H, ring proton), 3.83 (bs, 
3 H, NH2, ring proton), 4.70 (d, 1 H, ring proton), 6.62 (d, 
2 H, Ar-H), 7.19 (d, 2 H, Ar-H); 13C NMR (DCCl3) ppm 
16.81, 18.79 (CH3 isopropyl), 29.15, 29.79 C(l,5), 32.25 
C(9), 46.61 (C-H isopropyl), 52.59, 54.22 C(2,4,6,8), 114.10 10 
127.21, 128.68, 147.18 (Ar-C), 170.47 (NC=O). Anal. 
Calcd for C17H25N3O: C, 71.05; H, 8.77; N, 14.62. Found: 
C, 70.67; H, 8.82; N, 14.28. The N-acetyl derivatve (108) 
was made from 51 and acetyl chloride in H2CCl2 in the 
standard fashion. This derivative (108) was converted to the 15 
hydroperchlorate (109) derivative (hygroscopic) in the usual 
manner. Anal. Calcd for C19H28CIN3O6.0.8: C, 51.036 H, 
6.71. Found: 51.27; H, 6.63. 
A flask was charged with amide 51 (2.0 g, 6.96 mmol) in 
ether and chilled to 5° C. HCI gas was added over a period 20 
of 10 minutes. The resulting white precipitate was filtered 
and washed with cold ether. Recrystallization 
(H3COH:ether) of the solid followed by filtering and drying 
afforded (1.58 g, 70.2%) of salt 2; mp 209°-210° C. IR 
(KBr) 3400, 3160 (N-H), 3010, 2940, 2860 (C-H), 1630 25 
(NC=O) cm-1; 1H NMR (D2O) ol.45 [d, 6 H, CH3 iso-
propyl], 2.03 lbs, 2 H, H(9)], 2.49 [bs, 2 H, H(l,5)]. 
3.40-3.67 [m, 9 H, H(2,4,6,8) and C-H isopropyl], 4.63 [s, 
2 H, N-H], 7.62 [m, 4 H, Ar-H]; 13C NMR (D2O) ppm 18.83 
[CH3 isopropyl], 29.84, [C(l,5)], 30.14 [C(9)], 52.19, 55.26 30 
[bs C(2,4,6,8)], 63.65 [C-H isopropyl], 124.20, 131.59, 
135.29, 139.39 [Ar-C], 177.42 [NC=O]. Compound 2 was 
hygroscopic. Anal. Calcd for C17H26N3OCI.0.9 H2O: C, 
20 
39.18 [SO2CH3], 46.76 [C-H isopropyl], 52.11. 52.52, 54.19 
[C(2,4,6,8)]. 119.80, 128.05, 128.16, 133.22, 138.21 [Ar-C], 
169.63 [NC=O]. The compound 52 was used directly to 
make 3. 
Solid 52 (3.1 g, 8.48 mmol) was dissolved in etllanol 
(95%, 50 ml), and the resulting solution was chilled (5° C.). 
With stirring, HClO4 (60%, 1.77 g, 10.60 mmol) was added 
dropwise to tile chilled solution over a period of 15 min. 
Stirring was continued an additional 10 min at this tempera-
ture. A white precipitate was filtered and recrystallized 
(H2O) to give 1.97 g (49.9%) of white platelettes of 3; mp 
267°- 268° C. IR (KBr) 3260, 3120 (N-H), 3010 (Ar-H), 
2940, 2880 (C-H), 1630 (NC=O), 1100 (Cl-O) cm-1. 1H 
NMR (DMSO-d6) ol.32 (dd, 2 H, CH3 isopropyl), 
1.69-1.87 [dd, 2 H, H(9)], 2.24 [m, 2 H, H(l,5)], 3.06 (s, 3 
H, SO2CH3), 3.18-3.55 (m, 9 H, ring protons, C-H isopro-
pyl), 7.24 (d, 2 H, Ar-H), 7.37 (d, 2 H, Ar-H), 7.93 (bs, 1 H, 
N-H), 10.05 (s, 1 H, CH3SO2N-H); 13C NMR (DMSO-d6) 
ppm 26.48 (CH3 isopropyl), 27.59 C(l,5,9), 39.52 (C-H 
isopropyl), 39.57 C(2,4,6,8), 59.53 (CH3SO2), 118.12, 
128.81, 130.60, 139.53 (Ar-C), 172.62 (NC=O). Mass 
spectral (EI) data calcd for C18H28N3SO7CI rn/e (M+): 
365.1773 (-HCIO4). Found: 365.1775. Anal. Calcd for 
C18H28CIN3SO7 ; C, 46.40; H, 6.06; N, 9.02; S, 6.88. Found: 
C, 46.40; H, 6.01; N, 8.94; S, 7.07. 
EXAMPLE VII 
3-(4-Fluorobenzoyl)-7-isopropyl-3,7-diazabicyclo-
[3.3.l]nonane Hydroperchlorate (4) and 
3-(4-Fluorobenzoyl)-7-isopropyl-3,7-diazabicyclo-
[3.3.l]nonane (53) 
In flask equipped witll a magnetic stirrer, an addition 54.23; H, 7.71;. Found: C, 54.56; H, 7.62. 
EXAMPLE VI 
3-( 4-Methanesulfonamidebenzoy 1)-7-isopropyl-3, 7-
diazabicyclo[3 .3 .l ]nonane Hydroperchlorate (3) and 
3-(4-Methanesulfonamidebenzoyl)-7-isopropyl-3,7-
35 funnel, a condensor with N2 inlet and a glass stopper were 
placed the amine 105 (2.53 g, 15.03 mrnol) andNaOH (10%, 
15.07 g, 37.58 mmol) in H2CCl2 (25 ml). A solution of 
4-fluorobenzoyl chloride (2.62 g, 16.54 mmol) in H2CCl2 
(15 ml) was added dropwise over a period of0.5 h under N2. 
diazabicyclo[3.3.l]nonane (52) 
A flask was equipped with an addition funnel, magnetic 
stirrer, condensor with N2 inlet, and an ice bath. To a chilled 
40 The mixture was allowed to stir an additional 3 h. Addition 
of H2O (50 ml) was followed by extraction with H2CCl2 
(3x50 ml). Combined extracts were dried (NazSO4), filtered, 
and concentrated to give a light yellow solid. Hash chro-
(5° C.) solution of amide 51 (3.0 g, 10.44 mrnol) and 45 
pyridine (0.87 g, 10.96 mmol) in H2CCl2 (20 ml) was added 
dropwise methanesulfonyl chloride (1.18 g, 10.34 mmol) in 
H2CCl2 (10 ml) over a 15 min period. After the addition was 
complete, the mixture was allowed to stir at RT overnight. 
Filtration of the solution removed traces of pyridine hydro- 50 
chloride, and the filtrate was transferred to a separatory 
funnel. Extraction (1 N NaOH, 4x40 ml) was followed by 
neutralization (pH-7) of the aqueous phase, and the remain-
ing organic layer was discarded. This neutral solution was 
extracted (H2CCl2, 4x40 ml), and the resulting solution was 55 
dried (Na2SO4) and filtered. After concentration, there was 
obtained 3.46 g (90.6%) of an off-white solid 52; mp 
89°-91 ° C. IR (KBr) 3140 (N-H), 3040 (Ar-H), 2980, 2930, 
2870, 2810 (C-H), 1610 (NC=O) cm-1. 1H NMR (DCCl3) 
o0.97 (d, 3 H, CH3 isopropyl), 1.08 (d, 3 H, CH3 isopropyl), 60 
1.69 lbs, 1 H, H(5)], 1.79 [bd, 2 H, H(9)], 1.98 [bs, 1 H, 
H(l)], 2.42 (d, 1 H, ring proton), 2.51 (d, I H, ring proton), 
2.60 (m, 1 H, CH isopropyl), 2.74 (d, 1 H, ring proton), 3.03 
(m, 5 H, ring protons, SO2CH3), 3.32 (d, 1 H, ring proton), 
3.78 (d, 1 H, ring proton), 4.76 (d, 1 H, ring proton), 65 
7.21-7.30 (q, 4 H, Ar-H); 13C NMR (DCCl3) ppm 16.26, 
19.16 (CH3 isopropyl), 28.89, 29.55 [C(l,5)], 32.05 [C(9)], 
matography of the oil was performed on neutral alumina (50 
g) with hexane:ethyl acetate (60:40) as tile eluent. The 
filtrate was concentrated and placed under vacuum to give 
3.88 g (89.0%) of amide 53 as a white solid; mp 87°-88° C. 
IR (KBr) 3090, 3005, 2975, 2930, 2860, 1630 (NC=O), 750 
cm-1. 1H NMR (DCCl3) 00.96 (d, 3 H, CH3 isopropyl), 1.07 (d, 3 H, CH3 isopropyl), 1.71 [m, 3 H, H(9), H(5)], 1.95 [s, 
1 H, H(l)], 2.41- 2.72 (m, 3 H, ring protons), 3.03 (d, 2 H, 
ring protons), 3.31 (d, 1 H, ring proton), 3.72 (d, 1 H, ring 
proton), 4.74 (d, 1 H, ring proton), 7.08 (m, 2 H, Ar-H), 7.36 
(m, 2 H, Ar-H); 13C NMR (DCCl3) ppm 16.26, 19.18 (CH3 
isopropyl), 28.97, 29.69 C(l,5), 32.16 C(9), 46.59 (C-H 
isopropyl), 52.12, 52.49, 54.65 C(2,4,6,8), 114.96, 115.25, 
128.77, 128.88, 133.60, 133.64 (Ar-C), 161.04, 164.33 
(J=248.2 Hz, ArC-F), 169.07 (NC=O). Mass spectral (El) 
data calcd for C17H23N2OF rn/z (M+): 290.1794. Found: 
290.1790. Anal. Calcd for C17H23N2OF: C, 70.32; H, 7.98; 
N, 9.65. Found: C, 70.39; H, 8.03; N, 9.71. 
To a chilled (5° C.) solution of amide 53 (1.0 g, 3.44 
mmol) in ether contained in a flask was added dropwise 
HCIO4 (60%, 0.72 g, 4.30mmol) over a period of5 minutes. 
This precipitate was filtered and washed with cold ether. 
Recrystallization (methanol) of the precipitate was followed 
by filtration and drying to give g(l .03 g, 76.3%) of salt 4 as 
5,468,858 
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white platelettes; mp 246°-247° C. IR (KBr) 3120 (N-H), 
3010 (Ar-H), 2940, 2880 (C-H), 1625 (NC=O) cm-1; 1H 
NMR (D3C-C==N) 61.38 (d, 6 H, CH3 isopropyl), 1.81 [d, 
1 H, H(5)], 2.29 [d, 3 H, H(5,9)], 3.34 [m, 5 H, ring protons, 
C-H isopropyl], 3.52 [bd, 4 H, ring protons], 7.17 [t, 2 H, 5 
Ar-H], 7.38 [m, 2 H, Ar-H]; 13C NMR (D3CC==N) ppm 
16.72 [CH3 isopropyl], 27.89 [C(l,5)], 28.99 [ C(9)], 50.34, 
53.52 lbs, C(2,4,6,8)], 60.96 [C-H isopropyl], 116.29, 
116.59, 118.01, 118.36, 130.65, 130.77, 132.78, 132.82 
[Ar-C], 162.59, 165.88 [J=247.6 Hz, ArC-F], 174.13 10 
[NC=O]. Mass specttral (El) data calcd for 
C17H24ClN2O5F rn/z (M+): 290.1855 (-HC1O4). Found: 
290.1853. Anal. Calcd for C17H24ClN2O5F: C, 52.24; H, 
22 
H, C-H imidazole), 9.20 (s, 1 H, C-H imidazole); 13C NMR 
(DMSO-d6 ) ppm 26.42, 27.36, 59.64 (ring carbons), 120.63, 
121.35. 122.01, 128.74, 135.27, 137.49(Ar-C), 171.49 
(NC=O); Mass spectral (El) data calcd for C20H28Cl2N4O9 
rn/z (M+): 338.2106 (-2 HC1O4). Found: 338.2099. Anal. 
Calcd for C2J!28Cl2N4O9 ; C, 44.54; H, 5.23; N, 10.38. 
Found: C, 44.75; H, 5.20; N, 10.20. 
EXAMPLE IX 
7-Isopropy 1-3-( 4-fluorophenacy 1)-3, 7-diazabicyclo-
[3 .3. l ]nonane (55) 
To a standard setup was added 2-chloro-4'-fluoroac-6.19. Found: C, 52.46; H, 6.24. 
EXAMPLE VITI 
3-{ 
4-(lH-Imidazol- l-yl)benzoyl]-7-isopropyl-3,7-diaza-
bicyclo[3.3. l] nonane Dihydroperchlorate (5) and 
3-[4-( lH-Imidazol-
15 etophenone (7.55 g, 43.8 mmol) and NaI (9.85 g, 65.7 
mmol) in H3CCN (30 ml) which was then heated for 30 
minutes with stirrring. The solution was allowed to cool to 
room temperature (30 min) which was followed by dropwise 
addition of amine 105 (6.7 g, 39.8 mmol) to give a light 
yellow mixture which was stirred overnight. Filtration (suc-20 
1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3. l ]-
nonane (54) 
A jacketed flask was equipped in the standard manner. To 25 
a solution of amide 53 (3.35 g, 11.54 mmol) in DMSO (50 
ml) was added imidazole (1.18 g, 17.30 mmol), potassium 
carbonate (anhydrous, 1.67 g, 12.12 mmol), and 18-crown-6 
(500 mg). The stirred mixture was heated at 110° C. for 40 
h under N2 with the use of boiling toluene in the jacket. 30 
Cooling the solution to RT was followed by addition of 
chilled H2O (75 ml). Combined extracts (H2 CC12 , 4x40 ml) 
of the suspension were washed with H2O (80 ml) and 
saturated NaCl (80 ml); the solution was then dried 
(N½S04 ). Filtration and concentration gave a light yellow 35 
solid 54 which was dried on a vacuum pump overnight. 
Flash chromatography (neutral alumina) of the crude solid in 
solution using ethyl acetate:hexane (2:3) caused the starting 
material to be eluted first. With a more polar solvent system 
[ethyl acetate:methanol (30:1)] product 54 could be isolated 40 
(1.35 g, 35.1 %) as an off white, gummy solid for which a 
melting point could not be determined since the material 
appeared to be hygroscopic. IR (KBr) 3400 (N-H), 3110 
(Ar-H), 2975, 2910, 2800 (C-H), 1620 (NC=O), 735 (para) 
cm-1. 1H NMR (DCC13) 60.96-1.14 [ dd, 6 H, CH3 isopro- 45 
pyl], 1.68 [dd, 1 H, H(9)], 1.81 [bs, 2 H, H(l,5)]. 2.02 [bs, 
1 H, H(9)], 2.45 [d, 1 H, ring proton], 2.57 [d, 1 H, ring 
proton], 2.63 [m, 1 H, C-H isopropyl], 2.77 [d, 1 H, ring 
proton], 3.09 [d, 2 H, ring protons], 3.38 [d, 1 H, ring 
proton], 3.76 [d, 1 H, ring proton], 4.79 [d, 1 H, ring proton], 50 
7.22[s, 1 H, C-H imidazole], 7.41-7.54 [dd, 4 H, Ar-H], 7.89 
[s, 1 H, imidazole]; 13C NMR (CDC13) ppm 16.33,19.41 
[CH3 isopropyl], 29.03,29.78 [ C(l,5)], 32.26[C(9)], 46.72 
[C-H isopropyl], 52.15, 52.61, 54.38, 54.82 [C(2,4,6,8)], 
118.07 [C-H imidazole], 121.15, 128.54 [Ar-C], 130.60, 55 
135.44 [C-H imidazole]. 136.91,137.43 [Ar-C], 168.80 
[NC=O]. This material was convened directly to a salt. 
Treatment of 54 (1.44 g, 4.25 mmol) with HC1O4 (60%, 
1.6 mmol) at 5° C. (ice bath) produced a white precipitate. 
Filtration, followed by recrystallization (methanol) of the 60 
solid, gave white needles (1.14 g, 60.9%) of 5; mp 
262°-263° C. IR (KBr) 3200 (N-H), 3005 (Ar-C), 2940, 
2880 (C-H), 1645 (NC=O), 1100 (Cl-O) (cm-1). 1H NMR 
(DMSO-d6 ) 61.33 [bs, 6 H, (H3C)zC], 2.34, 2.41 [d, 2 H, 
H(9)], 2.79 (bs, 1 H, NH), 3.03 [s, 2 H, H(l,5)], 3.23, 3.97 65 
[bs, 9 H, H(2, 4, 6, 8), C-H isopropyl], 7.66 (d, 2 H, ArH), 
7.94 (s, 1 H, C-H imidazole), 7.96 (d, 2 H, ArH), 8.32 (s, 1 
tion) removed excess NaI and the filtrate was diluted with 
H2O and transferred to a separatory funnel. The resulting 
homogenous solution (pH-5) was extracted (ether, 3x75 ml) 
with the latter being discarded, and the pH of the aqueous 
layer was adjusted to 12 using 10% NaOH. Extraction 
(ether, 3x 75 ml) of the aqueous layer was followed by 
another extraction (H2CC12 , 3x75 ml) and the ether extracts 
were discarded. The organic layer (H2CC12 ) was dried 
(N½S04 , 2 h), filtered, and concentrated (rotary evaporator) 
to give 2.9 g (86.1 %) of amine 55 as a light yellow solid; mp 
193°-194° C. IR (KBr) 3060, 3040 (Ar-H), 2940, 2805 
(C-H), 1700 (C=O) cm-1; 1H NMR (DCC13 ) d 1.45 (d, 6 H, 
CH3 isopropyl), 1.81 [d, 1 H, H(9)a,J, 2.11 [d, 1 H, H(9)eq], 
2.32 lbs, 2 H, H(l,5)], 2.85 (d, 2 H, ring protons), 3.37 (d, 
2 H, ring protons), 3.49 (d, 2 H, ring protons), 3.86 (m, 3 H, 
ring protons, C-H isopropyl), 4.18 (s, 2 H, ArC(O)CH2), 
7.15 (t, 2 H, Ar-H), 8.02 (m, 2 H, Ar-H); 13C NMR (DCC13) 
ppm 17.01 (CH3 isopropyl), 28.04 [C(l,5)], 30.05 [C(9)], 
53.74, 57.2257.34 (ring carbons, C-H isopropyl), 62.22 
[ArC(O)CH2], 115.58, 115.88, 130.57, 130.70, 131.22, 
131.26 (Ar-C), 164.10, 167.49 (J= 265.8 Hz, ArC-F), 194.99 
(C=O). Ketone 55 was slightly unstable, and thus was 
reduced to the corresponding alcohol 110. 
EXAMPLEX 
(±)-3-[( 4'-Fluoro )-1-hydroxy- l-phenylethyl]-7-iso-
propyl-3, 7-diazabicyclo[ 3.3.l]nonane (110) 
To a standard setup was added solid LiA1H4 (95%, 0,787 
g, 19.7 mmol) in one portion. After purging the flask with N2 
for 10 min, tetrahydrofuran (10 ml) was poured slowly over 
the LiAIH4 which resulted in a gray slurry. Ketone 55 (2.0 
g, 6.57 mmol) was added portionwise over a period of 15 
min, followed by heating the reaction mixture (40° C., 3 h) 
and then stirring at room temperature overnight. Excess 
LiAlH4 was destroyed using EtOAc (10 ml) added dropwise 
to the chilled (5° C.) reaction mixture. Addition of 5% HCl 
(-15 ml) adjusted the aqueous solution to pH-2 which was 
then extracted (ether, 2x 30 ml) to remove small impurities 
and these ether extracts were discarded. After making the 
aqueous phase slightly basic (pH-8) using 10% NaOH (-10 
ml), extraction (H2CC12, 3x50 ml) was followed by washing 
the organic layer with H2O (75 ml), said NaCl (75 ml), and 
dried (Na2SO4 , 2 h). Filtration and concentration (rotary 
evaporator) resulted in 1.33 g (66.2%) of racemic alcohol 
110 as a white solid; mp 53°-54° C. IR (film) 3225 (OH), 
2930, 2800 (C-H), 1600 (C=C) cm-1; 1H NMR (DCC13) 
5,468,858 
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lil.08 (d, 6 H, CH3 isopropyl), 1.57 lbs, 2 H, H(9)], 1.87 lbs, 
2 H, H(9)], 2.26 (m, 2 H, ring protons), 2.45 (d, 2 H, ring 
protons), 2.55 [dd,J= 4.09 Hz, 2 H, ArCH(OH)CH2], 2.83 
(bs, 2 H, ring protons), 3.07 (m, 3 H, ring protons, C-H 
isopropyl), 4.67 [dd, J= 4.09 Hz, 1 H, ArCH(OH)], 6.23 (bs, 5 
1 H, O-H), 7.01 (t, 2 H, Ar-H), 7.35 (m, 2 H, Ar-H); 13C 
NMR (DCC13) ppm 18.39, 18.69 (CH3 isopropyl), 30.17, 
30.90 [C(l,5)], 32.54 [C(9)], 54.07, 54.38, 54.61, 55.24 
[C(2,4,6,8)1, 59.55 (C-H isopropyl), 64.47 [Ar-
CH(OH)CH2], 68.54 [ArC-H(OH)], 114.71, 114.99, 127.39, 10 
127.49, 138.97, 139.00 (Ar-C), 160.28, 163.51 (J=243.9 Hz, 
ArC-F); Anal. Calcd for C18H27FN2O: C, 70.56; H, 8.88. 
Found: C, 70.28; H, 9.00. 
24 
ethanedithiol (33.59 g, 356.6 mmol), p-toluenesulfonic acid 
(16.28 g, 85.58 mmol) and benzene (200 ml) were added, 
and the resulting mixture was heated at reflux for 40 h. The 
solvent was then removed through a Dean-Stark trap, and 
the resulting oil was dissolved in H2O. The aqueous layer 
was extracted (ether, 2x100 ml), the extracts being dis-
carded. Basification (pH-12) of the aqueous solution was 
achieved using 10% NaOH, followed by extraction (ether, 
4x75 ml). The organic layer was washed with NaOH (1 N) 
and then brine. After drying (NazSO4 ) the solution, evapo-
ration afforded 8.06 g (75.2%) of a light yellow oil which 
was 3,7-diisopropyl- 9,9-(1,3-dithiolan-2-yl)-3,7-diazabi-
cyclo[3.3.1] nonane (111). IR (film) 2905, 2800 (C-H)cm-1 
2905, 2800 (C-H). Since IR analysis showed no carbonyl 
EXAMPLE XI 
3, 7-Diisopropyl-3, 7-diazabicyclo[3.3. l ]nonane 
Hydroperchlorate (10) 
3,7-Diisopropyl-3,7-diazabicyclo[3.3.l]nonane (59) 
15 band, the oil 111 was used directly to prepare 11 without 
further purification. 1 H NMR of this oil showed: (DCC13 ) 
61.03 [d, 12 H, CH3 isopropyl], 2.26 [d, 4 H, ring protons], 
2.77 [m, 2 H, C-H isopropyl], 2.89 [dd, 4 H, ring protons], 
3.08 [s, 4 H, S-CH2]; 13C NMR (DCC13 ) ppm 17.97 [CH3 
A jacketed flask was equipped with a magnetic stirrer, a 
heating mantle, a condensor, a lower takeoff condensor with 
20 isopropyl], 37.39 [C(l,5)], 43.11 [S-CHz], 51.20 [C(2,4,6, 
8)], 53.21 [C-H isopropyl], 70.89 [C(9)]. 
N2 inlet and two glass stoppers. To a solution of ketone 47 
(5.9 g, 20.3 mmol) in triethylene glycol (50 ml) was added 
KOH pellets (85%, 13.89 g, 210.9 mmol) and hydrazine 25 
(95%, 3.55 g, 105.19 mmol). The stirred mixture was heated 
at 200°-210° C. for 4 h under N2with the use of boiling 
tetralin in the jacket. Cooling the solution to RT was 
followed by addition of chilled H2O. Combined extracts 
(ether, 4x80 ml) of the suspension were washed with 10% 30 
NaOH and saturated NaCl, was then dried (NazSO4). Fil-
tration and concentration gave an oil which was placed 
under vacuum. Anew yellow oil 59 resulted (4.48 g, 81.l %). 
IR (KBr) 2975, 2900, 2820 (C-H), cm-1 • IR analysis of 
compound showed no carbonyl stretch spectrum, and thus 35 
59 was used directly to prepare salt 10. 
A flask was equipped with a magnetic stirrer and an ice 
bath. To a chilled (5° C.) solution of amine 59 (3.4 g, 16.16 
mmol) in dry ether (150 ml) was added HC1O4 (60%, 3.4 g, 
20.2 mmol) dropwise over a period of 15 min. The mixture· 40 
was allowed to stir an additional 15 min at 0°-5° C. A white 
precipitate formed and was filtered and washed (cold ether, 
30 ml). The solid was recrystallized (methanol), and white 
needles were collected and washed (cold methanol) and 
45 dried to give 3.63 g (72.3%) of salt 10 (hygroscopic); mp 
211 °-212° C. IR (KBr) 2985, 2940, 2850, 1090 (Cl-O) 
cm-1; 1H NMR (D3C-C==N) Ii 1.14 [, d, 12 H, CH3 
isopropyl], 1.80 [bs, 2 H, H(l,5)], 2.21 [bs, 2 H, H(9)], 2.97 
[d, 4 H, ring protons], 3.19 [m, 2 H, C-H isopropyl], 3.28 [d, 
50 4 H, ring protons]; 13C NMR (D3C-C==N) ppm 17.11 [CH3 
isopropyl], 28.56 [C(l,5)], 31.41 [C(9)], 54.26 [C(2,4,6,8)], 
56.13 [C-H isopropyl]. Mass spectral (EI) data calcd for 
C13H27N2O4Cl m/z (M+): 210.2096. Found: 210.2096. 
Anal. Calcd for C13H27N2O4Cl.0.2 H2O C, 49.66; H, 8.78; 
N, 8.91. Found: C, 49.33; H, 8.52; N, 9.31. 55 
· EXAMPLE XII 
Into a flask equipped with a magnetic stirrer and an ice 
bath was placed thioketal 111 (8.06 g, 26.82 mmol) in dry 
ether (100 ml), and the solution was cooled to 0°-5° C. To 
the stirred mixture was added dropwise HC1O4 (60%, 5.61 
g, 33.52 mmol) over a period of 15 min. After stirring an 
additional 15 min at 5° C., a white precipitate was filtered 
and washed (cold ether). Recrystallization (methanol) 
afforded, after drying, hydroperchlorate 11 as white needles 
(6.72 g, 62.5%); mp 222.0°-223.0° C. IR (KBr) 2990, 2940, 
2860, 1080 (Cl-O) cm-1. 1H NMR (DCC13 ) 61.18 (d, 12 H, 
CH3 isopropyl), 2.31 [bs, 2 H, H(l,5)], 3.32-3.57 [m, 15 H, 
N-H, H(2,4,6,8)=-eq• C-H isopropyl, S-CH2]; 13C NMR 
(DCC13) ppm 16.78 (CH3 isopropyl), 39.29 C(l,5), 41.23 
(S-CH2), 52.29 C(2,4,6,8), 54.64 (C-H isopropyl), 70.22 
C(9). Mass spectral (El) data calcd for C15H29N2S2O4Cl m/e 
(M+): 300.1694 (-HCIO 4 ). Found: 300.1695. Anal. Calcd 
for C15H29ClN2S2O4 : C, 44.93; H, 7.29; N, 6.99; S, 15.99 
Found: C, 45.10; H, 7.33; N, 6.91; S, 15.80. 
EXAMPLE XIII 
3-Benzoyl-7-cyclopropylmethyl-3, 7-diazabicyclo-
[3.3. l ]nonane Hydroperchlorate (12) and 
3-Benzoy 1-7-cyclopropylmethyl-3, 7-diazabicyclo-
[3 .3.1 ]nonane (60) 
Into a flask equipped with a magnetic stirrer, an addition 
funnel, a condensor with N2 inlet, and a glass stopper were 
placed the amine 106 (5.50 g, 30.51 mmol) and NaOH (10%, 
30.60 g, 76.28 mmol) in H2CC12 (25 ml). A solution of 
benzoyl chloride (4.72 g, 33.56 mmol) in H2CC12 (15 ml) 
was added dropwise over a period of 0.5 h under N2. The 
mixture was allowed to stir an additional 3 h. Addition of 
H2O (50 ml) was followed by extraction with H2CC12 (3x50 
ml). Combined extracts were dried (NazSO4), filtered, and 
concentrated to give a yellow oil. Flash chromatography of 
the oil was performed on neutral alumina (50 g, 60-ml fritted 
funnel, suction) with ethyl acetate as the eluent. The filtrate 3, 7-Diisopropy 1-9 ,9-(1,3-dithiolan-2-y 1)-3, 7-diaza-
bicyclo[3 .3. I ]nonane Hydroperchlorate (11) and 
3,7-Diisopropyl-9,9-( 
1,3-dithiolan-2-yl)-3, 7-diazabicyclo[3 .3 .1 ]nonane 
(111) 
60 was concentrated and placed under vacuum to give 7.15 g 
(82.4%) of amide 60 as an oil which was used directly to 
prepare 12. IR (film) 3090, 3005 (Ar-H), 2920, 2860, 2775 
(C-H), 1630 (NC=O), 715 aromatic mono-substitution) 
A flask was equipped with a magnetic stirrer, condensor 65 
with a N2 inlet, a Dean-Stark trap, and a heating mantle. 
After addition of the ketone 47 (8.0 g, 35.66 mmol), 1,2-
cm-1 . 1H NMR (DCC13) 60.11 [d, 2 H, cyclopropyl 
CH2c=>], 0.49 [t, 2 H, cyclopropyl CH2ceq)], 0.92 [m, 2 H, 
cyclopropyl C-H], 1.74 [m, 3 H, H(5,9)1, 1.98 [bs, 2 H, 
H(l), CH2 cyclopropyl], 2.23 [bs, 3 H, H(4,6)<=>' CH2 
5,468,858 
25 
cyclopropyl], 2.94 [d, 1 H, H(6)ceqJ], 3.01 [d, 1 H, H(2)<=J], 
3.28 [m, 2 H, H(8)c=l' H(4)ceqJ], 3.78 [d, 1 H, H(8\eqJ], 4.79 
[ d, 1 H, H(2)ceql], 7.38 [m, 5 H, Ar-H]; 13C NMR (DCC13) 
ppm 2.85, 4.11 [ cyclopropyl CH2], 7.95 [cyclopropyl C-H], 
28.64, 29.01 [(C(l,5)], 31.72 [C(9)], 46.02 [ C(2)], 51.74 5 
[C(8)], 57.71, 57.98 {C( 4,6)], 63.68 [CH2 cyclopropyl], 
126.13, 127.64, 128.07, 137.20 [Ar-C], 169.68 [NC=O]. 
A flask was equipped with a magnetic stirrer and an ice 
bath. To a chilled (5° C.) solution of the amide 60 (7.15 g, 
25.14 mmol) in dry ether (120 ml) was added dropwise lO 
HC1O4 (60%, 5.26 g, 31.43 mmol) over a 10-min period 
followed by stirring for an additional 10-min. Filtered salt 12 
(a white solid) was washed with dry, cold ether. The white 
solid was recrystallized (methanol). Filtration and drying 
afforded 6.30 g (65.1 %) of pure salt 12; mp 236.0°-237.0° 15 
C. IR (KBr) 3150 (N-H), 3020 (Ar-H), 2880 (C-H), 2840, 
1630 (NC=O), 1095 (Cl-O) cm-1 ; 1H NMR (DMSO-d6 ) 
o0.47 (bd, 2 H, CH2ax cyclopropyl), 0.71 (d, 2 H, CH2eq 
cyclopropyl), 1.16 (m, 1 H, C-H cyclopropyl), 1.81 [dd, 2 H, 
H(9)], 2.28 [bs, 2 H, H(l,5)], 3.32-2.97 (m, 8 H, ring 20 
protons, NCH2 cyclopropyl), 3.66 (bd, 2 H, ring protons), 
7.95 (m, 5 H, Ar-H); 13C NMR (DMSO-d6) ppm 5.27 (C-H 
cyclopropyl), 26.45, 27.66, 62,56 (ring carbons), 126.95, 
128.22, 129.33, 136.08 (Ar-C), 172.69 (NC=O). Mass 
spectral (El) data for C18H25ClN2O5 m/e (M+): 284.1888 25 
(-HC1O4). Found: 284.1888. Anal. Calcd for 
C18H25ClN2O5: C, 56.18; H, 6.55. Found: C, 55.92; H, 6.57. 
EXAMPLE XIV 
30 
26 
mmol) in dry ether (150 ml) was added HC1O4 (60%, 3.41 
g, 20.39 mmol) dropwise over a period of 15 min. The 
mixture was allowed to stir an additional 15 min at 0°-5° C. 
A white precipitate formed and was filtered and washed with 
cold ether. The solid was recrystallized (methanol), and 
white needles were collected and washed (cold methanol, 25 
mi) and dried (Abderhalden, 80° C./0.2 mm Hg, 12 h) to 
give 4.3 g (71.1%) of salt 13; mp 190°-191° C. IR (KBr) 
3060, 3005 (ArH), 2910 2820 (C-H), 1100 (Cl-O), 735, 710 
(C-H out of plane, mono) cm-1. 1 H NMR (DMSO-d6) o 0.46 
[m, 2 H, (CH2)ax, cyclopropyl ring], 0.62 [m, 2 H, (CH2)eq' 
cyclopropyl ring], 1.07 [m, 1 H, (CH), cyclopropyl ring], 
1.64 [d, J= 11.4 Hz, 1 H, H(9)mJ, 1.77 [d, J= 11.4 Hz, 1 H, 
H(9)eq], 2.42[d, J= 11.1 Hz, 2 H, H(6,8)ax], 2.85 (d, J=7.2 
Hz, 2 H, CHrcyclopropyl), 3.09 [m, 4 H, H(2,4)0 X' H(6, 
8)eq], 3.54 [bs, 4 H, CH2-Ar, H(2,4)eq], 7.31-7.43 (m, 5 H, 
Ar-H); 13C NMR (DMSO-d6 ) ppm 3.87 (CH2, cyclopropyl 
ring), 6.07 (CH, cyclopropyl ring), 27.46 [C(6)], 29.58 
[C(l,5)], 57.01, 56.84 [C(2,4,6,8)], 60.56 (CH2-Ar), 61.49 
(CHz-cyclopropyl), 127.57, 128.39, 129.32, 136.49 (Ar-C). 
Mass spectral (EI) data calcd for C18H27ClN2O4 mfe (M+): 
270.2096 (-HC1O4). Found: 270.2093. Anal. Calcd for 
C18H27ClN2O4 : C, 58.29; H, 7.34. Found: C, 58.39; H, 7.30. 
EXAMPLE XV 
3-(4-Chlorobenzoyl)-7-cyclopropylmethyl-3,7-diaza-
bicyclo[3.3.l]nonane Hydroperchlorate (14) 
and 
3-( 4-Chlorobenzoyl)-7-cyclopropylmethy 1-3, 7-diaza-
bicyclo[3.3.1 ]nonane (62) 
A flask was equipped with a magnetic stirrer, a condensor 
with N2 inlet, an addition funnel, and two glass stoppers. To 
7-Benzyl-3-cyclopropylmethyl-3,7-diazabicyclo-
[3.3.l]nonane Hydroperchlorate (13) and 
7-Benzyl-3-cyclopropylmethyl-3,7-diazabicyclo-
[3.3.l]nonane (61) 
A jacketed flask was equipped with a magnetic stirrer, a 
heating mantle, a condensor, a lower takeoff condensor with 
35 a mixture of amine 106 (4.03 g, 22.35 mmol) in H2CC12 (25 
ml) and 10% NaOH (22.41 g, 55.88 mmol) was added 
dropwise a solution of 4-chlorobenzoyl chloride (4.30 g, 
24.59 mmol) in H2CC12 (15 ml) over a period of 30 min. N2 inlet, and two glass stoppers. To a solution of ketone 48 
(9.53 g, 33.51 mmol) in triethylene glycol (100 ml) was 
added KOH pellets (85%, 17.7 g, 268.08 mmol) and hydra- 40 
zine (95%, 4.52 g, 134.04 mmol). The stirred mixture was 
heated at 160°-170° C. for 4 h under N2 via the use of 
boiling tetralin in the jacket. Cooling the solution to RT was 
followed by addition of chilled H2O (100 ml). Combined 
extracts (ether, 4x80 ml) of the suspension were first washed 45 
with 10% NaOH (80 ml) and saturated NaCl (80 ml) and 
then dried (NazSO4). Filtration and concentration gave a 
light yellow oil 61 (8.99 g, 98.2%) which was placed under 
vacuum. The oil 61 gave the following spectral data. IR 
(film) 3090, 3010, 3005 (ArH), 2920, 2780 (C-H), 735, 700 50 
(C-H out of plane, mono) cm-1; 1HNMR (DCC13 ) 80.14 [m, 
2 H, (CH2)ax, cyclopropyl ring], 0.51 [m, 2 H, (CH2 )eq, 
cyclopropyl ring], 0.94 [m, 1 H, (CH), cyclopropyl ring], 
1.52 [dd, J= 19.8 Hz, 2 H, H(9)], 1.91 [m, 2 H, H(l,5)], 2.20 
(d, J = 6.6 Hz, 2 H, CH2-cyclopropyl), 2.33 [dd, J= 10.7 Hz, 55 
J=3.6 Hz, 2 H, H(6,8)axl, 2.41 [dd, J=l0.8 Hz, J= 4.8 Hz, 2 
H, H(2,4)mJ, 2.76 [d, J=l0.5 Hz, 2 H, H(6,8)eq], 2.85 [d, 
J=l0.5 Hz, 2 H, H(2,4)eq], 3.49 (s, 2 H, Ar-CH2), 7.21-7.45 
(m, 5 H, Ar-H); 13C NMR (DCC13 ) ppm 3.90 (CH2, cyclo-
propyl ring), 8.72 (CH, cyclopropyl ring), 29.43 [C(9)], 60 
30.22 [C(l,5)], 57.68 [C(2,4), 57.90 [C(6,8)], 62.75 (Ar-
CH2), 64.04 (CH2-cyclopropyl), 126.38, 127.92, 128.62, 
139.74 (Ar-C). Spectral analysis showed no carbonyl group 
Stirring of the mixture was continued for an additional 3 h 
under N2. To the heterogenous mixture was added H2O (100 
ml) and two layers separated. Further extracts (H2CC12 , 
3x50 ml) of the aqueous layer were combined, dried 
(NazSO4), filtered and concentrated to give a viscous yellow 
oil. Flash chromatography of the oil was performed on 
neutral alumina (50 g) using hexane:ethyl acetate (60:40) as 
the eluent. The filtrate was concentrated and then placed 
under vacuum to give 4.18 g (83.1 %) of off-white solid 62; 
mp 67°-68° C. IR (KBr) 3090, 3005 (ArH), 2920, 2880, 
2770 (C-H), 1635 (NC=O), 760 (C-H out fo plane, para) 
cm-1 . 1H NMR (DCC13 ) o 0.12 [m, 2 H, (CH2)=, cyclo-
propyl ring], 0.54 [m, 2 H, (CH2)eq' cyclopropyl ring], 0.91 
[m, 1 H, (CH), cyclopropyl ring], 1.73 [m, 3 H, H(5), H(9)], 
2.02 [m, 2 H, H(l), CH2-cyclopropyl], 2.24 [m, 3 H, H(4)ax, 
H(6)ax, CHz-cyclopropyl], 2.96 [d, J= 10.5 Hz, 1 H, H(6)eql, 
3.03 [d, J= 13.2 Hz, 1 H, H(2)axl, 3.28 [m, 2 H, H(8) 0 x, 
H(4)eql, 3.75 [d, J=13.2 Hz, 1 H, H(8)eql 4.83 [d, J=l3.2 Hz, 
1 H, H(2)eq], 7.39 (s, 4 H, Ar-H); 13C NMR (DCC13) ppm 
3.21, 4.43 (CH2 , cyclopropyl), 8.29 (CH,cyclopropyl), 29.01 
[C(l)], 29.41 [ C(5)], 32.10 [C(9)], 46.59 [C(2)], 52.16 
(C(8)], 58.10 [C(4)], 58.38 [C(6)], 64.25 (CHz-cyclopropyl), 
128.15, 128.28, 134.40, 135.90 (Ar-C), 169.06 (NC=O). 
Mass spectra (El) data calcd for C18H23ClN2O m/e (M+): 
318.1499. Found: 318.1498. Anal. Calcd forC 18H23ClN2O: 
in the IR or C-13 NMR spectrum, and thus this oil 61 was 
used without further purification to prepare salt 13. 
C, 67.81; H, 7.27; N, 8.79. Found: C, 67.53; H, 7.25; N, 
65 8.72. 
A flask was equipped with a magnetic stirrer and an ice 
bath. To a chilled (5° C.) solution of amine 61 (4.41 g, 16.31 
To a flask HC1O4 (60%, 0.66 g, 3.92 mmol) was added 
dropwise to a chilled (5° C.) solution of amide 62 (1.0 g, 
5,468,858 
27 
3.14 mmol) in ether over a 5 minute period. The resulting 
precipitate was filtered and washed with cold ether. Recrys-
tallization (methanol) followed by filtration and drying 
afforded 1.02 g (77.1 % ) of salt 14 as white needles; mp 
231°-232° C. IR (KBr) 3180 (N-H), 3095, 3020 (Ar-H), 5 
2950, 2880 (C-H), 1620 (NC=O), 1090 (Cl-O) cm-1; 1H 
NMR (D3C-O=N) 60.51 [d, 2 H, cyclopropyl CH2cax)J, 0.82 
[d, 2 H, cyclopropyl CH2ceq)], 1.18 [m, 1 H, cyclopropyl 
C-H], 1.85 [d, 1 H, H(9)], 2.33 lbs, 3 H, H(l,5,9)), 3.03 [d, 
2 H, CH2 cyclopropyl], 3.29 [m, 4 H, ring protons], 3.74 (bs, 10 
2 H, ring protons], 4.09 [bs, 2 H, ring protons], 7.36 [d, 2 H, 
Ar-HJ, 7.48 [d, 2 H, Ar-HJ; 13C NMR (D3CO=N) ppm 4.94, 
6.40 [cyclopropyl CH2], 27.89 [C(l,5)], 29.05 [C(9)], 57.42, 
63.98, 64.08 [ring carbons], 118.37, 129.67, 129.79, 129.95, 
135.08, 136.29 [Ar-C], 173.85 [NC=O). Anal. Calcd for 15 
C18H24N2O5Cl2: C, 51.56; H, 5.77. Found: C, 51.34; H, 
5.85. 
28 
ring], 2.26 [bs, 2 H, H(l,5)], 3.01 [m, 4 H, H(2,4)=' 
CH2-cyclopropyl], 3.31-3.46 [m, 8 H, H(6,8)ax, H(2,4)eq, 
SCH2], 3.73 (s, 2 H, Ar-CH2). 3.92 [dd, 2 H, H(6,8)eq], 
7.28-7.45 (m, 5 H, Ar-H); 13C NMR (DCCl3) ppm 4.29 
(CH2, cyclopropyl ring), 6.10 (CH, cyclopropyl ring), 39.19, 
39.35 (SCH2), 41.73 [C(l,5)], 56.12 [C(2,4)], 56.92 [C(6, 
8)), 60.96 (Ar-CH2), 60.99 (CH2-cyclopropyl), 69.42 
[C(9)], 128.04, 128.57, 129.89, 135.09 (Ar-C). Mass spectra 
(El) data calcd for C2JI29ClN2O4S2 m/e (M+): 360.1694 
(-HC1O4). Found: 0.1703. Anal. Calcd. for 
C2Jl29ClN2O4S2: C, 52.10; H, 6.34; N, 6.08; S, 13.91. 
Found C, 51.98; H, 6.30; N, 5.81; S, 14.05. 
EXAMPLE XVII 
7-Benzyl-3-cyclopropylmethyl-3,7-diazabicyclo-
[3.3.l]nonan-9-one (48) 
A flask was equipped with a magnetic stirrer, a heating 
mantle, an addition funnel, a condensor with N2 inlet, and a EXAMPLE XVI 
7-Benzyl-3-cyclopropylmethyl-9,9-(1,3-dithiolan-2-yl)-
3, 7-diazabicyclo[3.3.1 ]nonane 
Hydroperchlorate (15) and 
7-Benzyl-3-cyclopropylmethyl-9,9-(1,3-dithiolan-2-yl)-
3,7-diazabicyclo[3.3.l]nonane (112) 
20 glass stopper. A mixture of cyclopropylmethylamine ( 4.44 g, 
62.4 mmol), HCl (37%, 3.07 g, 31.2 mmol), glacial acetic 
acid (3.75 g, 62.4 mmol) and parformaldehyde (3.94 g, 
131.04 mmol) in deoxygenated (N2 bubbled in for 2 h) 
methanol (125 ml) was stirred at reflux for 15 min under N2. 
25 A solution of N-benzyl-4-piperidinone (102, 11.8 g, 62.4 
mmol) and glacial acetic acid (3.75 g, 62.4 mmol) was added 
dropwise over a period of 1.5 h. After 10 h at reflux, the 
mixture was treated with additional paraformaldehyde (3.94 
A flask was equipped with a magnetic stirrer, condensor 
with a N2 inlet, a Dean-Stark trap, and a heating mantle. 
After addition of the ketone 48 (6.0 g, 21.09 mmol), 1,2-
ethanedithiol (19.87 g, 210.9 mmol), p-toluenesulfonic acid 30 
(9.63 g, 50.6 mmol) and benzene (120 ml) were added, and 
the resulting mixture was heated at reflux for 30 h. The 
solvent was removed through a Dean-Stark trap and the 
resulting oil was dissolved in H20 (100 ml). The aqueous 
layer was extracted (ether, 2x50 ml) and the extracts were 35 
discarded. Basification of the aqueous solution (pH-12) was 
achieved using an aqueous 10% NaOH solution. This new 
solution was extracted (ether, 4x75 ml) and the extracts were 
then washed with NaOH (1 N, 90 ml) and saturated NaCl (90 
ml). After drying (N8zSO4), the organic solution was evapo- 40 
rated to afford 6.44 g (84.7%) of 112, a light yellow oil; IR 
(film) 3080, 3010, 3000 (ArH), 2905, 2800 (C-H), 730, 705 
(C-H out of plane, mono) cm-1; 1H NMR (DCC13) 60.14 [m, 
2 H, (CH2),,,., cyclopropyl ring], 0.51 [m, 2 H, (CH2 )eq' 
cyclopropyl ring], 0.92 [m, 1 H, (CH), cyclopropyl ring], 45 
2.15 [m, 2 H, H(l,5)], 2.27 (d, 2 H, CH2-cyclopropyl), 
2.73-2.84 (m, 8 H, ring protons), 3.14 (s, 4 H, SCH2), 3.53 
(s, 2 H, Ar-CH2), 7.24-7.46 (m, 5 H, Ar-H); 13C NMR 
(DCC13) ppm 3.83 (CH2, cyclopropyl ring), 8.60 (CH, 
cyclopropyl ring), 37.93, 37.98 [C(l,5)], 43.51 (SCH2), 50 
56.56 [C(2,4)], 56.67 [C(6,8)], 61.68 (CH2-Ar), 62.49 (CH2-
cyclopropyl), 71.91 [C(9)], 126.60, 128.02, 128.62, 139.34 
(Ar-C). Thioketal 112 was used without further purification 
to prepare salt 15. 
Into a flask equipped with a magnetic stirrer and an ice 55 
bath was placed thioketal 112 (6.44 g, 17.86 mmol) in dry 
ether (100 ml), and the solution was cooled to 0°-5° C. To 
the stirred mixture was added dropwise perchloric acid 
(60%, 3.73 g, 22.32 mmol) over a period of 15 min. After 
stirring an additional 15 min at 5° C., a white precipitate was 60 
filtered and washed with cold ether (25 ml). Recrystalliza-
tion (methanol) and drying afforded hydroperchlorate 15 as 
white needles (3.34 g, 40.6%); m.p. 147.5°-149.0° C. IR 
(KBr) 3090, 3010 (ArH), 2940, 2850 (C-H), 1100 (Cl-O), 
735, 705 (C-H out of plane, mono) cm-1. 1H NMR (DCC13) 65 
60.59 [m, 2 H, (CH2)=, cyclopropyl ring], 0.68 [m, 2 H, 
(CH2 )eq, cyclopropyl], 0.98 [m, 1 H, (CH), cyclopropyl 
g, 131.04 mmol) in one portion. Heating at reflux was 
continued for another 19 h. Upon cooling to RT, concentra-
tion of the solution gave an orange oil which was redissolved 
in H2O (100 ml). Extracts (ether, 2x75 ml) of the aqueous 
solution were discarded. The aqueous layer was chilled (5° 
C.) and then made basic (pH-12) with NaOH pellets. 
Extraction (H2CC12, 3x 75 ml) gave a solution which was 
dried (N8zSO4), filtered, and concentrated to a viscous, 
reddish-orange oil. Distillation of the oil under reduced 
pressure (175-190C/1CJ5 mm Hg) gave 13.54 g (76.3%) of 
a light yellow oil which solidified upon standing at -10° C.; 
mp 56.0°-57.5° C. This solid was recrystallized (pentane) to 
give an analytical sample of 48; mp 58.5°-59.5° C. IR (KBr) 
3090, 3070, 3030 (Ar-H), 3005 (C-H, cyclopropyl), 2975, 
2910, 2830 (C-H), 1740 (C=O), 1600, 1495 (ArC=C), 
740, 710 (C-H out of plane, mono) cm-1; 1H NMR (DCC13) 
60.12 [dq, 2 H, (C-H)=, cyclopropyl ring], 0.51 [dq, 2 H 
(C-H)eq' cyclopropyl ring], 0.89 [m, 1 H, (C-H), cyclopropyl 
ring], 2.32 (d, 2 H, CH2-cyclopropyl), 2.59 [m, 2 H, H(l,5)], 
2.81 [dd, 1= 10.8 Hz, 1=5.6 Hz, 2 H, H(6,8)axJ, 2.94 [dd, 1= 
10.8 Hz, 1=6.8 Hz, 2 H, H(2,4)=], 3.04 [dd, 1=10.8 Hz, 
1=3.2 Hz, 2 H, H( 6.8)eq], 3.12 [dd, 1= 10.8 Hz, 1= 3.2 Hz, 
2 H, H(2,4)eq], 3.57 (s, 2 H, CH2Ph), 7.38-7.22 (m, 5 H, 
Ar-H), 13C NMR (DCC13) ppm 3.76 (CH2, cyclopropyl 
ring), 8.53 (CH, cyclopropyl ring), 46.76 [C(l,5)], 58.19 
[C(2,4)], 58.36 [C(6,8)], 61.11 (CH2Ph), 61.85 (CH2-cyclo-
propyl), 127.08, 128.22, 128.66, 138.54 (Ar-C), 214.85 
[C=O]; 15N NMR (DCC13) ppm 36.17 [N(7)], 37.74 
[N(3)]; Mass spectral (El) data calcd for C18H24N2O 
m/e(M+): 284.1188; Found: 284.1190. Anal. Calcd for 
C18H24N2O: C, 76.02; H, 8.51; N, 9.85. Found: C, 76.19; H, 
8.46; N, 9.99. 
EXAMPLE XVIII 
3,7-Diisopropyl-3,7-diazabicyclo[3.3.l]nonan-9-one 
(47) 
A flask was equipped with a magnetic stirrer, a heating 
mantle, an addition funnel a condensor with N2 inlet and a 
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glass stopper. A mixture of isopropylamine (8.87 g, 150.0 
mmol) HCl (37%, 7.39 g, 75.0 mmol), glacial acetic acid 
(9.01 g, 150.0 mmol) and parformaldehyde (9.46 g, 315.0 
mmol) in deoxygenated (N2 bubbled in for 2 h) methanol 
(125 ml) was stirred at reflux for 15 min under N2 • A solution 5 
of N-isopropyl-4-piperidinone (101, 21.18 g, 150.0 mmol) 
and glacial acetic acid (9.01 g, 150.0 mmol) was added 
dropwise over a period of 1.5 h, which was followed by a 
period of boiling for an additional 23 h. After the initial 10 
h of heating, paraformaldehyde (9.46 g, 315.0 mmol) was 10 
added in one portion to the mixture. Concentration of the 
solution (after 23 h) gave an orange oil which was redis-
solved in H2O (150 ml), and extracts (ether, 2x100 ml) 
thereof were discarded. The aqueous layer was chilled (5° 
C.) in an ice bath and made basic (pH-12) with NaOH 15 
pellets. Extraction (H2CC12, 3x75 ml) gave a solution which 
was dried (NazSO4), filtered, and concentrated to give a 
viscous, reddish-orange oil. Distillation of the oil under 
reduced pressure (110°-120° c.110-5 mm Hg) gave 22.53 g 
(67.3% of a light yellow oil 47. IR (film) 2975, 2910, 2830 20 
(C-H), 1735 (C=O) cm-1 . 1H NMR (DCC13 ) 8 1.02 (d, 12 
H, CH3 isopropyl), 2.58 [m, 2 H, H(l,5)], 2.87 [m, 6 H, 
H(2,4,6,8)ax, C-H isopropyl], 3.04 [dd, 4 H, H(2,4,6,8)eq]; 
13C NMR (DCC13) ppm 17.9, 18.2 (CH3 , isopropyl), 46.82 
C(l.5), 53.17 (C-H isopropyl), 53.27, 53.36 C(2,4,6,8), 215 25 
C(9). Anal. Calcd for C13H24N2O: C, 69.59; H, 10.78; N, 
12.49. Found: C, 69.39; H, 10.61; N, 12.21. 
30 
EXAMPLE XX 
7-Benzyl-3-thia-7-azabicyclo[3.3.1 ]nonane 
Hydrochloride (113) 
This amine salt was prepared by the general method 
outlined in U.S. Pat. No. 4,581,361 
EXAMPLEXXI 
3-[ 4-(Nitro )pheny lacety 1 ]-7-isopropy 1-3, 7-diaza-
bicyclo[3 .3 .1 ]nonane (94) 
A standard setup was used with a N2 inlet. Initially, the 
amine 105 (2.42 g, 14.38 mmol) in H2CC12 (35 ml) was 
added followed by NaOH (10%, 14.42 g, 35.95 mmol) 
which resulted in a heterogenous mixture. To this mixture 
was added 4-nitrophenylacetyl chloride (3,16 g, 15.82 
mmol) dropwise over a 15-min period. Stirring was contin-
ued for an additional 3 h upon which the brown mixture was 
transferred to a separatory funnel, and the layers were 
separated. The aqueous layer was extracted (H2CC12 , 3x25 
ml), and the organic layers were combined. After drying 
(Na2SO4 , 2 h), the organic solution was filtered and con-
centrated to give 94 as a light brown solid (3.3 g, 69.2 %); 
mp 93°-94°]C. IR (KBr) 3090 (Ar-H), 2960, 2920, 2800, 
2740 (C-H), 1625 (NC=O) cm-1 ; 1H NMR (DCC13 ) d 0.94 
(dd, 6 H, CH3 isopropyl), 1.69 [q, 2 H, H(9)], 1.92 [bs, 2 H, 
EXAMPLE XIX 
3-Cyclopropy lmethyl-3, 7-diazabicyclo[3 .3 .1 ]nonane 
(106) 
30 H(l,5)], 2.46 [m, 3H, ring protons, C-H, isopropyl), 2.79 (d, 
1 H, ring proton), 2.93 (td, 2 H, ring protons), 3.39 (d, 1 H, 
ring proton), 3.79 (s, 2 H, CH2-Ar), 3.84 (d, 1 H, ring 
proton), 4.57 (d, 1 H, ring proton), 7.44 (d, 2 H; Ar-H), 8.15 
(d, 2 H, Ar-H); 13C NMR (DCC13 ) ppm 16.83, 18.44 (CH3 
35 isopropyl), 28.76, 29.42 [C(l,5)1, 31.57 [C(9)], 40.62 (CH2-
Ar), 46.76 (C-H isopropyl), 50.60, 52.78, 54.03, 54.42 
[C(2,4,6,8)], 123.37, 130.02, 143.58, 146.56 (Ar-C), 167.93 
(NC=O). Amide 94 was used without further purification. 
A flask was equipped with a magnetic stirrer, a heating 
mantle, a condensor with N2 inlet, and two glass stoppers. 
The flask was initially flushed with N2 for a period of 15 
min. Palladium-on-carbon (10%, 0.997 g, 30 mg of catalyst/ 
mmol of the amine) was added in one portion, and the 40 
system was flushed with N2. Dry and deoxygenated CH3OH 
was slowly poured over the catalyst (CAUTION: catalyst 
can ignite in presence of air). To the stirred solution were 
added amine 61 (8.99 g, 33.24 mmol) and anhydrous 
HCO2NH4 (5.24 g, 83.1 mmol), and the resulting mixture 45 
was boiled under N2 for 30 min. Cooling the mixture to RT, 
and filtering through a celite pad, was followed by concen-
tration of the resulting solution to give an off-white, viscous 
oil. The oil was then dissolved in H2O and made basic 
(pH-12) using 10% NaOH. Combined extracts (CC14 , 4x60 50 
ml) of the aqueous solution were dried (Na2SO4), filtered 
and concentrated to give a yellow oil 106 (5.50 g, 91.8%); 
IR (film) 3300 (N-H), 3090, 3010 (CH2 cyclopropyl), 2900, 
2860, 2780 (C-H) cm-1; 1H NMR (DCC13) 80.13 [m, 2 H, 
(CH2)ax, cyclopropyl ring], 0.52 [m, 2 H, (CH2 )eq' cyclo- 55 
propyl ring], 0.87 [m, 1 H, (CH), cyclopropyl ring], 1.64 [m, 
2 H, H(l,5)], 1.82 [md, 2 H, H(9)], 2.07 (d, J= 6.6 Hz, 2 H, 
CH2-cyclopropyl), 2.31 [td, J= 11.1 Hz, 2 H, H(6,8)axl, 2.94 
[td, J= 13.8 Hz, 2 H, H(2,4)axl, 3.09 [ d, 1=13.2 Hz, 2 H, 
H(6,8)eq], 3.17 [d, J= 11.1 Hz, 2 H, H(2,4)eq], 4.09 [bs, 1 H, 60 
(N-H)]; 13C NMR (DCC13) ppm 3.76 (CH2 , cyclopropyl 
ring), 8.76 (CH, cyclopropyl ring), 29.87 [C(9)], 33.23 
[C(l,5)], 52.45 [C(6.8)], 59.51 [C(2,4)], 64.32 (CHz-cyclo-
propyl). NMR data showed the absence of the benzyllic 
group, and thus 106 was used without further purification to 65 
prepare amides 60 and 62 and their hydroperchlorates 12 
and 14, respectively. 
EXAMPLE XXII 
3-( 4-(Nitro )phenylacetyl]-7-isopropyl-3, 7-diaza-
bicyclo[3.3.1 ]nonane Hydroperchlorate (95) 
A solution of amide 94 (0.55 g, 1.66 mmol) in ether (40 
ml) contained in a flask equipped with a ice bath and a 
magnetic stirrer was chilled (5° C.) with stirring. Upon 
dropwise addition of HC1O4 (60%, 0.35 g, 2.07 mmol) a 
white precipitate resulted which was allowed to stir for 15 
min at this temperature. After filtering, the solid was recrys-
tallized (minimum amount of hot H3COH-20 ml), filtered, 
and allowed to stand at room temperature. This new solid 
was filtered (suction) and dried (Abderhalden, 80° C./7 mm 
Hg) to give 0.52 g (72.6%) of salt 95; mp 225°-226° C. IR 
(KBr) 3160 (N-H), 3090 (Ar-H), 2980, 2940 2890 (C-H), 
1665 (NC=O), 1100 (Cl-O) cm31 1; 1H NMR (D3CCN), d 
1.31 (d, 6 H, CH3 isopropyl), 1.82 [d, 1 H, H(9)axl, 1.95 [d, 
1 H, H(9)eq]2.36 [s, 2 H, H(l,5)]3.22 (m, 4 H, rig protons), 
3.49 (m, 3 H, ring protons, C-H isopropyl), 3.94 (bs, 2 H, 
Ar-CH2), 4.18 (bd, 2 H, ring protons), 7.47 (d, 2 H, Ar-H), 
8.28 (d, 2 H, Ar-H); 13C NMR (D3CCN) ppm 16.79 (CH3 
isopropyl), 27.79 [C(l,5)], 28.53 [C(9)], 41.09 (Ar-CH2), 
48.32, 53.81 [bs, C(2,4,6,8)], 60.95 (C-H isopropyl), 118.33, 
124.17, 132.02, 144.58 (Ar-C), 173.96 (NC=O); Anal. 
Calcd for C18H26ClN3O7 : C, 50.06; H, 6.07. Found: C, 
49.76; H, 6.16. 
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EXAMPLE XXIII 
3-[ 4-( Amino)phenylacetyl]-7-isopropyl-3, 7-diazabicyclo 
[3.3.1 ]nonane (96) 
To a flask equipped with a magnetic stirrer was added 5 
amide 94 (5.4 g, 16.3 mmol) in AcOH/H2O (1:1, 80 ml). 
After obtaining a homogenous solution, TiC13 (12%, 135.3 
g, 114.1 mmol) was added in one portion, and this purple 
solution stirred at room temperature for 7 min. Upon cooling 
(ice bath, 5° C.) the reaction mixture, 20% NaOH was added 
until a dark blue color persisted (pH-12). Extraction 10 
(HCC13, 3xl00 ml) was followed by washing of the organic 
layer with H2O (150 ml) and satd NaCl (150 ml). The 
organic layer was dried (N½SO4 , 3 h), filtered, and concen-
trated to give 96 (4.03 g, 82.1 %) as a light yellow, viscous 
oil. IR (film) 3350, 3240 (N-H), 3040 (Ar-H), 2980, 2930, 15 
2800 (C-H), 1630 (NC=O) cm-1; 1H NMR (DCC13) d 0.93 (dd, 6 H, CH3 isopropyl), 1.61 [q, 2 H, H(9)], 1.82 [d, 2 H, 
H(l,5)], 2.32-2.49 (m, 3 H, ring protons, C-H isopropyl), 
2.71 (d, 1 H, ring proton), 2.86 (d, 1 H, ring proton), 2.92 (d, 
1 H, ring proton), 3.25 (d, 1 H, ring proton), 3.58 (q, 2 H, 20 
Ar-CH2), 3.69 (bs, 2 H, NH2), 3.83 (d, 1 H, ring proton), 
4.51 (d, 1 H, ring proton), 6.58 (d, 2 H, Ar-H), 7.01 (d, 2 H, 
Ar-H); 13C NMR (DCC13) ppm 16.48, 18.06 (CH3 isopro-
pyl), 28.46, 29.01 [C(l,5)], 31.15 [C(9)], 40.20 (Ar-CH2), 
46.14 (C-H isopropyl), 50.13, 52.52, 53.51, 53.89 [C(2,4,6, 25 8)), 114.75, 125.58, 129.04, 144.71 (Ar-C), 169.80 
(NC=O). Amine 96 was used directly without further 
purification to prepare sulfonamide 97. 
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H3COH/ether 1:1, 40 ml), and the resulting solution was 
chilled (5° C.). With stirring, HC1O4 (60%, 0.95 g, 5.70 
mmol) was added dropwise over a period of 15 min and 
stirring was continued an additional 10 min at this tempera-
ture. The white precipitate was filtered and recrystallized 
(hot H3COH-25 ml)to give 1.54 g (70.7%) of 98 as white 
platelettes; mp 177:5°-178.5° C. IR (KBr) 3250 (N-H), 
3160 (N-H), 3020 (Ar-H), 2940, 2920, 2860 (C-H), 1665 
(NC=O), 1100 (Cl-O) cm-1; 1H NMR (D3CCN) d 1.28 (d, 
6 H, CH3 isopropyl), 1.79 [d, 1 H, H(9)aJ, 1.92 [d, 1 H, 
H(9),q], 2.33 [bs, 2 H, H(l,5)], 2.96 (s, 3 H, SO2CH3), 
3.11-3.28 (m, 4 H, ring protons), 3.44 (m, 3 H, ring protons, 
C-H isopropyl), 3.78 (bs, 2 H, Ar-CHz), 4.19 (d, 2 H, ring 
protons), 6.58 (bs, 1 H, N-H), 7.23 (m, 4 H, Ar-H), 7.60 (s, 
1 H, SO2 N-H); 13C NMR (D3CCN) ppm 16.67 (bs, CH3 
isopropyl), 27.79 [C(l,5)], 28.55 [C(9)1, 39.56 (SO2CH3), 
40.86 (Ar-CHz), 48.30, 53.80 [ bs, C(2,4,6,8)], 60.88 (C-H 
isopropyl), 121.93, 131.56, 132.88, 137.38 (Ar-C), 174.94 
(NC=O). Anal. Calcd for C19H30ClN3O7S: C, 47.55; H, 
6.30. Anal. Calcd for C19H30ClN3O7S.0.4 H2O: C, 46.84; H, 
6.37. Found: C, 46.55; H, 6.26. 
EXAMPLE XXVI 
3-[ 4-(N-acetyl)phenylacetyl]-7-isopropy 1-3, 7-diaza-
bicyclo[ 3.3.l]nonane (99) 
To a standard setup equipped with a with N2 inlet, was 
added a mixture of amide 96 (2.0 g, 6.63 mmol) in H2CC12 EXAMPLE XXIV 
3-[ 4-(Methylsulfony !)amino ]phenylacetyl-7-isopropyl-
3, 7-diazabicyclo[3.3 .l ]nonane (97) 
30 
(25 ml) and 10% NaOH (6.65 g, 16.58 mmol). To this 
mixture was added dropwise a solution of acetyl chloride 
(0.57 g, 7.30 mmol) in H2 CC12 (5 mi) over a period of 15 
min. Stirring (magnetic) of the mixture was continued for an A standard setup was equipped with a N2 inlet. To a 
chilled (5° C.) solution of amide 96 (2.1 g, 6.97 mmol) and 
pyridine (0.58 g, 7.32 mmol) in H2CC12 (20 ml) was added 35 
dropwise methanesulfonyl chloride (0. 79 g, 6.90 mmol) in 
H2CC12 (10 ml) over a 15 min period. After the addition was 
complete, the mixture stirred at RT overnight. Filtration of 
the mixture removed traces of pyridine hydrochloride, and 
the filtrate was transferred to a separatory funnel. Extraction 
0 (1 N NaOH, 4x40 ml) was followed by neutralization 4 
(pH-7) of the aqueous phase using acetic acid, and the 
remaining organic layer was discarded. This neutral solution 
was extracted (H2CC12, 4x40 ml), dried (N½S04 , 2 h) and 
filtered. After concentration, sulfonamide 97 was obtained 
2.32 g (87.4%) as an off-white solid; mp 73°-74° C. IR 45 
(KBr) 3140 (N-H), 3050 (Ar-H), 2980, 2920, 2880, 2800 
(C-H), 1630 (NC=O) cm-1; 1H NMR (DCC13) d 0.94 (dd, 
6 H, CH3 isopropyl), 1.69 [dd, 2 H, H(9)], 1.93 [bs, 2 H, 
H(l,5)], 2.41 (d, 1 H, ring proton), 2.52 (m, 2 H, ring proton, 
C-H isopropyl), 2.84 (d, 1 H, ring proton), 2.93 (m, 6 H, ring 50 
protons, SO2CH3), 3.38 (d, 1 H, ring proton), 3.66 (s, 2 H, 
Ar-CH2), 3.90 (d, 1 H, ring proton), 4.59 (d, 1 H, ring 
proton), 7.11 (dd, 4 H, Ar-H), 7.37 (s, 1 H, SO2N-H); 13C 
NMR (DCC13) ppm 17.17, 18.31 (CH3 isopropyl), 28.84, 
29.47 [C(l,5)], 31.62 [C(9)], 38.76 (SO2CH3), 40.05 (Ar- 55 
CH2), 46.89 (C-H isopropyl), 50.58, 53.04, 54.07, 54.30 
[C(2,4,6,8)], 121.66, 130.13, 132.44, 135.68 (Ar-C), 169.77 
(NC=O). Amide 97 was used without further purification to 
prepare hydroperchlorate 98. 
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additional 3 h under N2. To the heterogenous mixture was 
added H2O (100 ml) and the two layers were separated. 
Further extracts (H2CC12, 3x30 ml) of the aqueous layers 
were combined and dried (N½SO4 , 1 h), filtered, and 
concentrated. The resulting oil was placed on a vacuum 
pump overnight (RT/0.2 mm Hg) to give 2.03 g (89.1%) of 
99 as an light yellow solid; mp 71 °-72° C. IR (KBr) 3300 
(N-H), 3080, 3050 (Ar-H), 2980, 2930, 2870, 2800 (C-H), 
1680 [NC(O)CH3], 1620 (NC=O) cm-1; 1HNMR (DCC13) 
d 0.94 (dd, 6 H, CH3 isopropyl), 1.68 [dd 2 H, H(9)], 2.11 
[s, 3 H, CH3C(O)], 2,40 (d, 1 H, ring proton), 2.49 (m, 2 H, 
ring proton, C-H isopropyl), 2.78 (d, 1 H, ring proton), 2.87 
(d, 1 H ring proton), 2.96 (d, 1 H, ring proton), 3.32 (d, 1 H, 
ring proton), 3.64 (d, 2 H, Ar-CH2), 3.87 (d, 1 H, ring 
proton), 4.55 (d, 1 H, ring proton), 7.08 (d, 2 H, Ar-H), 7.36 
(d, 2 H, Ar-H), 8.70 (s, 1 H, N-H); 13C NMR (DCCl3) ppm 
16.99, 18.33 (CH3 isopropyl), 24.13 [CH3C(O)], 28.83, 
29.39 [C(l,5)], 31.55 [C(9)], 40.49 (Ar-CH2), 46.75 (C-H 
isopropyl), 50.62, 53.02, 53.99, 54.28 (Ar-C), 168.89 [NH-
C(O)CH3], 169.94 (NC=O). Amide 99 was used directly to 
prepare hydroperchlorate 100 without further purification. 
EXAMPLE XXVII 
3-[ 4-(N-acety l)pheny lacetyl]-7-isopropy 1-3, 7-diaza-
bicyclo[3 .3 .1 ]nonane Hydroperchlorate (100) 
A chilled (5° C., via ice bath) solution of amide 99 (2.03 
g, 5.91 mmol) in H3COH/ether (50:50, 25 ml) was contained 
in a flask equipped with a magnetic stirrer. Addition of 
HCIO4 (60%, 0. 72 g, 4.30 mmol) dropwise over a period of 
5 min was followed by continual stirring at this temperature 
EXAMPLE XXV 
3-[4-(Methylsulfonyl)amino]phenylacetyl-7-isopropyl-
3, 7-diazabicyclo[ 3 .3.1 ]nonane 
Hydroperchlorate (98) 
To a flask equipped with a magnetic stirrer and an ice bath 
was added sulfonamide 97 (1.73 g, 4.56 mmol) dissolved in 
65 for an additional 15 min. This precipitate was filtered and 
washed with cold ether. Recrystallization (H3COH, 35 ml) 
of the precipitate gave a new solid which was filtered and 
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dried (80° C./0.2 mm Hg, 12 h) to give 1.98 g (75.4%) of salt 
100 as white platelettes; mp 197°-198° C. IR (KBr) 3360 
(N-H), 3100 (N-H), 3040 (Ar-H), 2940, 2860 (C-H), 1675 
[NHC(O)CH3], 1645 (NC=O), 1100 (Cl-O) cm-1; 1HNMR 
(D3CCN) d 1.24 (d, 6 H, CH3 isopropyl), 1.78 [d, 1 H, 5 
H(9)=1.91 [d, 1 H, H(9)eq], 2.06 [s, 3 H, NC(O)CH3 ], 2.29 
[bs, 3 H, H(l,5), ring proton], 3.02-3.26 (m, 3 H, ring 
proton, C-H isopropyl), 3.43 (m, 3 H, ring proton), 3.72 (s, 
2 H, Ar-CH2), 4.19 (d, 2 H, ring protons), 7.18 (d, 2 H, 
Ar-H), 7.51 (d, 2 H, Ar-H), 8.36 (bs, 1 H, CH3C(O)N-H); 10 
13C NMR (D3CCN) ppm 16.75 (CH3 isopropyl), 24.29 
[NC(O)CH3], 27.81 [C(l,5)], 28.60 [C(9)], 41.11 (Ar-CH2), 
48.31, 53.95 [bs, C(2,4,6,8)1, 60.86 (C-H isopropyl), 
120.54, 130.72, 131.16, 138.77 (Ar-C), 169.56 [NH-
C(O)CH3 ], 175.01 (NC=O). Anal. Calcd for 15 
C2Jf30ClN3O6 : C, 54.11; H, 6.81. Anal. Calcd for 
C2Jf30CIN3O6 .0.8 H2O: C, 52.41; H, 6.95. Found: C, 
52.52; H, 6.92. 
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-continued 
Antiarrhythmic Properties of Selcted Representative 
3,7-Diheterabicylo[3.3.l]nonanes and Derivatives In Dogs with 
Myocardial Infarctions And Induced Ventricular Tachycardia 
Results Observed with SVT 3 mg/kg or 
Compda 6 mg/kg of Body Weight of the Dog 
108 
109 
Lldo-
caine 
Increased HVk; Increased MBP'; Prevented SVT in 
some dogs but not in others; (Class I AAA° activity) 
Increased RVERPb; Increased MBP; Markedly 
slowed SVT or abolished SVT; highly selective action 
on ischemically damaged tissue; lack of a negative 
inotropic action in vitro and in vivo (Class I and Class 
III AAA° activity and with very low proarrhythmic 
actiond) 
Lowered MBP; showed marked proarrhythmic action 
in all of the dog models 
BIOLOGICAL RESULTS 
ax = Cl04 , Cl, Br, HSO4 , citrate, fumarate, maleate 
bVERP = Ventricular effective refractory period 
"HR = Heart rate in beats/minute (bpm) 
20 dProarrhythmic action means agent increased rate of existing SVT or a new 
and faster SVT was inducible 
"AAA = Antiarrhythmic activity 
'NSVT = Nonsustained ventricular tachycardia (or abolished ventricular 
tachycardia) 
•SVT = Sustained ventricular tachycardia induced by programmed electrical 
To illustrate the useful biological properties of the com-
pounds described in this invention, selected derivatives were 
screened for antiarrhythmic agent (AAA) activity using dog 
models. A a standard for comparison purposes, we tested the 
DHBN members described herein against a commonly used 
antiarrhythmic agent, lidocaine, as well as against 7-benzyl-
3-thia-7-azabicyclo[3.3.l]nonane hydroperchlorate (114) 
[U.S. Pat. No. 4,581,361], and 7-benzyl-3-thia-7-azabicyclo 
[3.3.l]nonane hydrochloride (113). The results summarized 30 
in the Table below show the range of antiarrhythmic activ-
ites observed. It should be emphasized that the members of 
the DBCN have a minimal of proarrhythmic activity which 
enhances their potential utility. The substituents attached to 
the DBCN skeleton and described in this document could 35 
25 facing of infarcted dog heart 
RVERP = Right ventricular effective refractory period 
not be predicted to elicit the remarkable multi-class antiar-
rhythmic activity observed and with such a low incidence of 
proarrhythmic activity. 
'MBP = Mean blood pressure 
;QT sinus = QT interval during spontaneous rhythm 
"HV = HIS Purkinj or intraventricular conduction time 
The claims and specifications delineated herein describe 
the invention, and the terms employed draw their meaning 
from the specifications presented. It is felt that the compo-
sitions of the present invention can be utilized individually 
or in combinations. It is clear from the Table that multi-class 
action (as defined by the Vaughn-Williams classification 
method) is present in the compositions in varying degrees. 
Administration of such compositions can be administered to 
by way of example, but not limited thereto, intraveneously, 
orally, by suppository, inhalation, and the like. Moreover, it 
40 is also felt that the compositions claimed possess useful 
--------------------- antiarrhythmic agent (AAA) activity or generally are 
Antiarrhythmic Properties of Selcted Representative b di b · I · all · h · · · 
3,7-Diheterabicylo[3.3.l]nonanes and Derivatives In Dogs with roa Y 10 og1c y active or t e respectve compos1t1on are 
Myocardial Infarctions And Induced Ventricular Tachycardia intermediates to useful anatiarrhythmic or biologically 
Results Observed with SVT 3 mg/kg or 
Compda 6 mg/kg of Body Weight of the Dog 
2 
3 
5 
11 
12 
13 
53 
62 
Increased VERP;b QT prolonged; Lowered HR" by 
10-30 beats/min; no proarrhythmic actiond 
(Class I and III AAA° activity) 
Increased VERP;b QT prolonged; Lowered HRc by 
5-15 beats/min 
(Class III AAA" activity) 
NSVT' (SVT• was abolished); (Class I and III AAA° 
activity) 
Increased VERPb; QT prolonged 30%, Lowered HRc 
by by 20-40 beats/min; prevented SVT• from being 
induced in dogs with SVT in a controlled state; no 
hemodynamic depression; prevented gernation of SVT•; 
(Class I and III AAA° activity) 
Increased VERPb; QT prolonged; NSVT' (SVT• was 
abolished); slight depression of intraventricular 
conduction; prevented induction of induced SVT"; 
(Class I and III AAA° activity) 
Increased RVERPh; QT not prolonged; Lowered HRc 
by 10 beats/min; prevented induction of induced SVT"; 
(Class I and III AAA° activity) 
Lowered HRc; Lowered MBP'; Class II AAA° activity 
possible 
No influence or QT sinu~; No influence on HRc 
Increased RVE~; QT prolonged; NSVT' (prevented 
generation of SVT•); (Class I and II AAA° activity) 
active species that are released or generated in situ as a result 
45 of administration of the composition. Descriptions of the 
dog models employed can be found in U.S. Pat. Nos. 
4,581,361; 4,778,892; 4,910,311; 4,980,468; 5,043,445; 
5.084,572; and 5,110,933. Technology for determining class 
activity can be found in "Electrophysiological Actions of 
50 BRB-1-28 in Canine Myocardiai Tissues", by E. Patteson, B. 
J. Scherlag, K. D. Berlin, and R. Lazzara in The Journal of 
Pharmacology and Experimental Therapeutics, volume 259, 
pages 558-656 (1991) and in "Comparative Electrophysi-
ological and Hemodynamic Actions of BRB-1-28 and 
55 Lidocaine in the Normal and Infarcted Dog Heart:, by B. J. 
Scherlag, E. Patterson, R. Lazzara, B. R. Bailey, Jr., M. D. 
Thompson, and K. D. Berlin in the Journal of Electrophysi-
ology, volume 2, pages 461-477 (1988). 
Having thus described and examplified the preferred 
60 embodiments with a degree of particularity, it is understood 
that the invention is not limited to the embodiments set forth 
herein for the purposes of exemplification, but it limited to 
the scope of the attached claims, including the full range of 
65 
equivalency to which each element thereof is entitled. 
We claim: 
1. 3-Alkyl-7-substituted -3-azabicyclo[3.3. l]nonan-
9-ones characterized by the formula: 
5,468,858 
35 
X=ClO4, Cl, Br, HS04, citrate, fumarate, or maleate; 
where Q= (H3C)iCHN, 
5 
10 
C6H5CH2N orn-C3H7N and orY=(H3C)2CHN, C6H5CH2N 15 
with the proviso that when either one of Q or Y is 
C6H5CH2N, then the other Q or Y group cannot be 
(H3C)iCHN or C6H5CH2N. 
2. 3-Alkyl-7-substituted-9,9-(l ,3-dithiolan-2-yl)-3-azabi-
cyclo[3.3.l ]nonanes characterized by the formula: 
s 
R-N J N-R' 
s 
[With and without HX and 2 HX] 
wherein 
20 
25 
30 
X= ClO4, Br, Cl, HSO4, citrate, fumarate, or maleate; 
R=(H3C)iCH- or cyclopropylmethyl and R'= 35 
(H3C)iCH- or C6H5CH2-. 
3. 3-Alkyl-7-substituted-3-azabicyclo[3.3. l] nonanes 
characterized by the formula: 
I \ \ 
Q Z Y [With and without HX or 2 HX] 
\ I I 
wherein 
X=ClO4, Cl, Br, HSO4, titrate, fumarate, or maleate; 
Q=(H3C)iCHN; 
Z= CH2; and 
Y=4-O2N---C6H4---C(O)N, 4-H2N---C6H4---C(O)N, 
4-AcHNC6H4-C(O)N, 4-H3CSO2NH---C6H4-
C(O)N, 4-F---C6H4---C(O)N, 4-O2N-
C6H4CH2C(O)N, 4-H2N---C6H4CH2C(O)N, 
4-AcHNC6H4CH2C(O)N, 
4-H3CSO2NHC6H4CH2C(O)N, 
N ,;:::'\N 
4_ ~ -C6!4-C(O)N, 4-F-C614C(O)CH2N, 
N ,;:::'\ 
4-~ N-C6!4-C(O)CH2N, 
40 
45 
50 
55 
60 
65 
36 
-continued 
N ,;:::'\ 
4-~ N-C614-CH(OH)-CH2N, 
N ,;:::'\ 
4-~ N-C6!4-CH(0Ac)-CH2N, 
or (H3C)iCHN. 
4. 3-Alkyl-7-substituted-3-azabicyclo[3.3.l] nonanes 
characterized by the formula: 
I \ \ 
Q Z Y [With and without HX or 2 HX] 
\ I I 
wherein 
X=ClO4, Cl, Br, HSO4, citrate, fumarate, or maleate; Q= 
Z----CH2; and 
4-AcHNC6H4CH2C(O)N, 
C(O)N, 
4-H2N---C~4CH2C(O)N, 
4-H3CSO2NH---C6H4-
N ,;:::'\ 
4-~ N-4!4-C(O)N,4-F-C6!4C(O)CH2N, 
N ,;:::'\ 
4-~ N-C614-C(O)CH2N, 
N ,;:::'\ 
4-~ N-C614-CH(OH)-CH2N, 
N ,;:::'\ 
4-~ N-C6!4-CH(OAc)-CH2N, 
(H3C)iCHN, or C6H5CH2N. 
5. 3-Alkyl-7-substituted-3-azabicyclo[3.3.1] 
characterized by the formula: 
I \ \ 
Q Z Y [With and without HX or 2 HX] 
\ I I 
wherein 
nonanes 
X=ClO4, Cl, Br, HSO4, citrate, fumarate, or maleate; 
Q=n-C3H7N; 
Z= CH2; and 
Y=4-O2N-C6H4-C(O)N, 
4-AcHNC6H4-C(O)N, 
4-H2N---C6H4-C(O)N, 
4-H3CSO2NH-C6H4-
5,468,858 
37 
C(O)N, 4-F-C6H4-C(O)N, 4-O2N-C6H4CH2C(O)N, 
4-H2N-C6H4CH2C(O)N, 4-AcHNC6H4CH2C(O)N, 
4-H3CSO2NHC6H4CH2C(O)N, 
5 
10 
38 
-continued 
N ,r\ 
4-~ N-C6!-4-CH(OH)-CH2N, 
N ,r\ 
4_ ~ N-C6!-4-CH(0Ac)-CH2N, 
* * * * * 
